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Introduction 
 
General Features of Renal Cell Carcinoma 
Based on the latest incidence and mortality data, renal cell carcinoma (RCC) is the sixth most 
frequent cancer form in males and tenth in females worldwide and is responsible more than 
140 000 cancer-related deaths globally in a year [1, 2], but the incidence shows significant 
regional differences [3]. The highest rate is registered in Europe and North America, while the 
lowest is seen in Africa and Oceania [1]. Considering European countries, the Czech Republic 
and the Baltic States have the highest RCC burden, while Hungary belongs to the middle-risk 
countries with a 1.03 cumulative risk [1]. RCC affects the elderly; namely, more than 70% of 
the cases are diagnosed in patients over 60 [4]. RCC rarely occurs under 40, and in such a 
situation, one should consider a cancer syndrome or a rare RCC subset. RCC is approximately 
twice frequent in males [5]; however, the reason for this is still not apparent and might be 
caused by distinct lifestyle and occupational factors [6].   
 
RCCs derive from the kidney tubules. Although the exact causes of sporadic RCC are still 
debated, there are some risk factors, which surely aggravate the carcinogenetic events in the 
renal tubules [7]. Smoking is a well-known one, and it was ascertained that it has a dose-
dependent effect as well [8]. The RCC risk in smoker men is 50% higher compared to never-
smoker ones, and this elevation might be associated with the chronic tissue ischemia induced 
by cigarette smoking [8]. Obesity turned out to be an RCC risk factor as well, and the risk 
increases by the body mass index [9], but the data are limited if the body fat distribution 
influences the RCC risk [10]. Decreased physical activity and RCC risk negatively correlate 
to each other [11]. Also, several studies conducted that alcohol consumption has a negative 
effect as well; nevertheless, this effect appears to be dose-dependent, like in the case of 
smoking [12]. Several occupational carcinogens were investigated, although the conclusions 
were somewhat conflicting, it was proved that the trichloroethylene exposure was associated 
with RCC carcinogenesis; and others like cadmium, uranium or radon had no relationship 
with RCC development [13]. Some medical conditions also increase the RCC risk [7]. One of 
these is the essential hypertension disease because several studies proved that hypertension 
elevates the risk of RCC; nevertheless, the reduction of elevated blood pressure by drugs 
could decrease this risk [14]. Patients with end-stage kidney disease (ESKD) or undergoing 
hemodialysis have a higher RCC risk [15] because in these damaged kidneys, acquired cystic 
9 
 
kidney disease (ACKD) can develop, and these cysts have a potential for malignant 
transformation [16]. Of all RCC cases, 2-4% are familial and belong to different kinds of 
cancer syndromes like von Hippel-Lindau (VHL) syndrome, hereditary leiomyomatosis, and 
renal cell carcinoma (HLRCC) syndrome, and tuberous sclerosis [16]. These are caused by 
different kinds of germline mutations in tumor suppressor genes. The most frequent syndrome 
is the VHL disease, which is resulted by mutations in the VHL gene and characterized by 
renal and pancreatic cysts, central nervous system (CNS) hemangioblastoma, clear cell RCC, 
pheochromocytoma, endolymphatic sac tumor, and epididymal cystadenoma [17]. The clear 
cell RCC seen in VHL syndrome is commonly multifocal and bilateral [17]. The average age 
at the time of the diagnosis is approximately 26 years, but it can vary significantly (from 
infancy to 70 years) [18]. The genetic alterations of RCC subsets and a summary of hereditary 
renal tumors are detailed in one of the following chapters. 
 
RCC is not a single disease, but a heterogeneous group of malignant tumors, and the different 
subtypes have their unique clinical features and morphological patterns [16]. Early 
classifications were based solely on the histological features of the tumors [19]. Pioneered by 
Gyula Kovács, the Heidelberg classification, distinguishing conventional, papillary, 
chromophobe, collecting duct, medullary, and unclassified types, took into account the 
genetic alterations as well and now is regarded as the forerunner of the modern renal tumor 
classifications [20]. Later, the 2004 WHO classification relied on the approach [21] and added 
new entities to the previous subsets. Nine years later, after a consensus conference organized 
by the International Society of Urological Pathology (ISUP), the Vancouver classification was 
published [22], which served the basis of the current 2016 WHO classification and defined 14 
RCC subtypes [16]. Also, at least seven so-called emerging entities have already been 
published in the literature (Table 1) [23].  In terms of categorization, the 2016 WHO 
classification integrated the clinical, histological, immunohistochemical, and genetic features 
of the tumors [16].  
At the same time, a new grading system was created as well, to replace the much-criticized 
Fuhrman grading system [24]. The Fuhrman grade was based on the size and shape of the 
nuclei and the presence of the nucleoli (Table 2), hence it was hardly reproducible; 
furthermore, its prognostic value was debated as well [25, 26]. The proposed, so-called 
ISUP/WHO grade is influenced solely by the presence of the nucleoli (Figure 1) [24]. 
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RCC subsets accepted in the 2016 WHO Classification [16]  
Clear cell carcinoma 
Multilocular cystic renal neoplasm of low malignant potential 
Papillary carcinoma (type 1, type 2 and not otherwise specified) 
Hereditary leiomyomatosis and renal cell carcinoma associated renal cell carcinoma 
Chromophobe carcinoma 
Collecting duct (of Bellini) carcinoma 
Renal medullary carcinoma 
Micropthalmia-associated transcription factor family translocation carcinomas 
Succinate dehydrogenase deficient carcinoma 
Mucinous tubular and spindle cell carcinoma 
Tubulocystic carcinoma 
Acquired cystic disease-associated carcinoma 
Clear cell papillary carcinoma 
Renal cell carcinoma, unclassified 
RCC subsets not listed in the 2016 WHO Classification [23] 
Transcription elongation factor B1 mutated carcinoma 
Thyroid-like follicular carcinoma  
ALK rearrangement-associated carcinoma 
Renal cell carcinoma with prominent smooth muscle stroma 
Renal cell carcinoma occurring in patients with prior neuroblastoma 
Eosinophilic, solid and cystic carcinoma 
Biphasic squamoid papillary carcinoma 
Atrophic kidney-like carcinoma 
Clear cell carcinoma with giant cells and emperipolesis 
Low-grade oncocytic renal tumor [CD117- negative, cytokeratin 7-positive] 
High-grade oncocytic renal tumor 
Warthin-like papillary carcinoma 
Table 1 Renal cell carcinoma subtypes listed and not listed in the 2016 WHO Classification. 
 
Fuhrman grading system [25] 
Grade Nuclei Nucleoli 
 Size (µm) Shape  
1 10 Round, uniform Absent 
2 15 Slightly irregular Observed at x400 magnification 
3 20 Obviously irregular Observed at x100 magnification 
4 >20 Bizarre, multilobed Heavy chromatin clump 
ISUP/WHO grading system [24] 
1 
Not taken into account 
Absent at x400 magnification 
2 Observed at x400, but not at x100 magnification 
3 Observed at x100 magnification 
4 Extreme nuclear pleomorphism and /or presence 
of giant cells and/or sarcomatoid transformation 
and/or rhabdoid change 
Table 2 Comparison of the Fuhrman and ISUP/WHO grading systems.  
 
However, a major limitation of the ISUP grading system is that it has prognostic value solely 
in clear cell RCC and papillary RCC tumors [24]. Another conventional prognostic factor is 
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the TNM staging system [27], which is composed of the local extension of the tumor (T), the 
involvement of the regional lymph nodes (N), and the presence of systemic dissemination 
(M). This system is edited, and time-by-time reviewed by the Union for International Cancer 
Control (UICC), and now the 8th edition is in use [28]. The ISUP investigated other 
prognostic factors like the presence of microscopic tumor necrosis, rhabdoid change, 
sarcomatoid transformation, and microvascular invasion (MVI) [24]. Sarcomatoid 
transformation means the presence of fusiform cells with high cytological and nuclear atypia; 
furthermore, the overall architecture often resembles an undifferentiated pleomorphic sarcoma 
[29]. This phenomenon can be seen in any of the above-listed RCC entities, and it is most 
commonly observed in collecting duct RCC [16]. Sarcomatoid transformation is a long 
known negative prognostic factor with a median survival of 4 to 9 months [30]. However, the 
sarcomatoid transformation was not proved to be an independent prognostic factor [29], hence 
according to the consensus decision, the underlying RCC subset must be identified, and the 
case has to be treated as a grade 4 tumor [24]. The rhabdoid change is another form of 
dedifferentiation seen in RCC [31]. The typical triad observed in rhabdoid differentiation 
includes an eosinophilic, paranuclear cytoplasmic inclusion composed of intermediate 
filaments, an excentric nucleus, and a prominent, cherry red nucleolus [31]. As the 
sarcomatoid transformation, the rhabdoid change can be noted in any RCC subset [16], and it 
is associated with a dismal clinical course [32]; hence the histopathological report should state 
 
Figure 1 The nuclear features seen in grade I (a), II (b), III (c), and IV (d) tumors, 
respectively. For a better understanding, all images have a magnification factor of 400x. 
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its presence [24]. It is essential to mention that RCC with a rhabdoid change differs from that 
of the malignant rhabdoid tumor of the kidney (MRTK) in children [33], namely the INI1 
gene is retained in the former, and a biallelic loss of INI1 characterizes the MRTK [16]. In 
RCC, the presence of tumor necrosis is commonly noticed; however, its exact mechanism is 
still unknown [24]. It was presumed that the necrosis might be caused by the insufficient 
vascular supply as a result of the tumoral overgrowth of the existing vasculature [34]. Another 
hypothesis suggested immune mechanism [35], and the vascular immaturity was considered 
as well [36]; however, a different theory stated that the necrosis was linked to the vascular 
remodeling observed during the tumor progression [37]. The presence of tumor necrosis 
inversely correlates with the patient outcome [38], but this seems to be subtype-specific 
because the studies reported so far did not find any link between the prognosis and the 
presence of necrosis in case of papillary RCC and chromophobe RCC (ChRCC) [39]. In clear 
cell RCC, this link between necrosis and an unfavorable clinical course was evident for a long 
time [40], and Delahunt et al. proposed a grading system that incorporated the presence of 
tumor necrosis, too [39]. It is accepted that all these negative prognostic features should be 
reported with a simple yes or no in the pathology report, but it is still debated whether the 
extension of these parameters has any influence on the prognosis [24]. Also, the minimum 
area occupied by a sarcomatoid transformation or a rhabdoid change, which exerts an effect 
on patient outcome, is still not clear. In general, sarcomatoid transformation and rhabdoid 
change are identified if they fill at least a low-power field; furthermore, their extent must be 
estimated; however, for the tumor necrosis, both macroscopic and microscopic features 
should be taken into account [24]. RCC, especially clear cell RCC has an arborized capillary 
network [16]; hence an MVI is commonly noticed; although the data vary, MVI is seen 
approximately in 20% of the cases [41]. Also, the accurate relevance of MVI is uncertain 
because most authors failed to prove a negative link between MVI and survival data in 
multivariate models [42]; therefore, the description of its presence is not mandatory, and it 
should be done according to the local guidelines [24]. 
 
In terms of clinical presentation and symptoms, RCC has many faces. The classic triad of 
macroscopic hematuria, costovertebral pain, and palpable renal mass [43] is observed quite 
rare nowadays because roughly 10% of the patients show these symptoms together [44]. 
Approximately 60% of the RCC patients are symptomless [45], and their tumors are 
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diagnosed incidentally by imaging studies performed for other reasons like trauma, follow-up 
of diabetes or hypertension [46]. Iron-deficient anemia is the consequence of long-term 
hematuria, and this complication is common when the tumor invaded the renal pelvis [43]. An 
invasion of the left renal vein might lead to a sudden onset varicocele, while tumor 
propagation to the inferior vena cava might induce a bilateral swelling of the lower 
extremities [47]. Hypercalcemia and hyperviscosity syndrome are unusual manifestations in 
RCC, and these are triggered by increased secretion of parathyroid hormone and 
erythropoietin, respectively [48]. Also, non-specific symptoms might be observed, including 
recurrent fever, weight loss, malaise, loss of appetite, and night sweats [44]. About 30% of 
patients show up with distant metastasis [47], and the most frequent organs are lungs, liver, 
bones, and brain. Importantly, RCC can give distant metastasis to quite unusual sites like the 
vagina, testis, or eyelid [43]. Also, in these patients, the first sign of an RCC can be produced 
by the metastasis like a pathologic bone fracture or a grand mal seizure in case of brain 
metastasis [44].     
 
Genetic Background of Renal Cell Carcinoma 
The first reports on genetic features of sporadic RCC were published in the late 1980s. At that 
time, Kovács and his co-workers observed by cytogenetic studies that the short arm of 
chromosome 3 (3p) is frequently lost in clear cell RCC [49]. Later, it turned out that the VHL 
gene located at the 3p25.3 band, is the critical tumor suppressor gene inactivated in clear cell 
RCC [50]. The inactivation can be happened by chromosomal deletion, gene point mutation, 
and/or promoter region hypermethylation [18]. The VHL gene encodes the VHL protein, 
which is the member of the VHL-elongin BC complex, and thereby it acts as a substrate of the 
E3 ubiquitin ligase [18]. The later one degrades the hypoxia-inducible factor 1-alpha (HIF1α) 
in normoxic circumstances [18]. However, in case of the loss of the VHL protein, the HIF1α 
remains intact and is relocated to the nucleus where HIF1α is associated with the aryl 
hydrocarbon receptor nuclear translocator protein, which is also known as the hypoxia-
inducible factor 1-beta (HIF1β) [18]. This heterodimeric protein complex formed acts as a 
transcription factor resulting in angiogenesis, increased cell survival, elevated mitotic activity 
and enhanced immune evasion (Figure 2) [18]. Additionally, other genes located on the 3p 
locus, namely PBRM1, BAP1, SETD2b, and KDM5C, promote the progression of clear cell 
RCC [16]. Investigations using high-out sequencing methods revealed a set of clear cell RCC 
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patients harboring no VHL-related anomalies [51]. This so-called VHL wild-type subgroup 
has a dismal clinical outcome, but it is still debated if these cases belong to clear cell RCCs or 
they have an unidentified genetic change and represent another RCC subset [52].  
 
Papillary RCC is rather considered as an umbrella term for those RCCs that have a papillary 
architecture being characterized by different genetic anomalies [16]. Type 1 papillary RCC 
harbors activating mutation or amplification of the c-MET gene [53], besides the gains of 
chromosome 3, 7, and 17, along with loss of chromosome Y [54] are observed roughly 80% 
of the cases. The distinction between type 1 papillary RCC and mucinous tubular and spindle 
cell carcinoma (MTSCC) might be problematic because they share some histopathological 
features, but the trisomies of the chromosome discussed above cannot be observed in MTSCC 
[16]. There is no specific chromosomal alteration for MTSCC, and the tumors investigated 
were mostly hypoploid with different kinds of chromosomal losses like chromosome 1, 4, 6, 
8, 9, 13, 15, and 22 [55]. The genetic changes identified in type 2 papillary RCC are much 
less consistent that observed in type 1 papillary RCC; namely, the tumor cells frequently have 
losses and/or gains of chromosome 1, 3, 4, 5, 6, 8, 9, 10, 11, 15, 18 and 22 [56]. A gain of 8q 
and an allelic imbalance of 9q13 band are associated with worse clinical outcomes [57]; 
nevertheless, CDKN2A and B, TERT, and NF2 genes are frequently altered in type 2 papillary 
 
Figure 2 A schematic illustration of the VHL-elongin BC complex in normoxic (a) and 
hypoxic conditions. Because of the inactivation of the VHL gene, the latter process is 
observed in clear cell RCC [18].  
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RCCs [53]. In the molecular signature of chromophobe RCC, multiple losses of whole 
chromosomes, including 1, 2, 6, 10, 13, 17, 21 or Y can be observed, and these alterations are 
not seen in oncocytoma which is the most important differential diagnosis of chromophobe 
RCC [58]. According to the current knowledge, clear cell papillary carcinoma (CCPRCC) has 
no specific genetic anomaly, and more importantly, it harbors no VHL-related changes [16, 
59]. In terms of translocation carcinoma, the critical genetic alteration detected is a 
rearrangement of the microphthalmia-associated transcription factors (MiTF), including the 
TFE3 and TFEB genes [16]. RCCs that are associated with TFE3 fusions are denominated as 
Xp11.2 translocation carcinomas, and the partner genes are most frequently the ASPL, NonO, 
TPRC, PSF and, CLTC [60-63], but currently next-generation sequencing (NGS) based 
investigation revealed other partners [64], too. For TFEB translocation carcinoma, the partner 
gene is the MALAT1; hence these tumors are regarded as t(6;11) carcinomas [16]. A 
homozygous loss of the fumarate hydratase gene is typical for HLRCC syndrome associated 
RCCs [65], and a similar mechanism is observed in succinate dehydrogenase deficient (SDH) 
RCCs. However, in these tumors, a loss of the SDH subunits encoding genes is the 
characteristic genetic feature [16, 66]. As regards renal medullary carcinoma, the bilateral loss 
of the INI1 gene is the hallmark genomic change [67]. For tubulocystic RCC, targeted NGS-
based investigations revealed mutations in 14 genes, and these involved mainly ABL1 and 
PDGFRA genes [68]. In terms of ACKD RCC, comparative genomic arrays and FISH studies 
discovered multiple chromosomal losses and gains, including chromosome 3, 7, 16, 17, and 
sex chromosomes [16]. The later findings help the differentiation between papillary RCC and 
ACKD RCC because chromosome Y is commonly deleted in papillary RCCs [54]. Collecting 
duct RCC harbors no consistent genetic change [16], but currently, by using molecular 
studies, it turned out that HER2 amplification [69], a homozygous deletion of CDKN2A and 
SLC7A11 genes are quite frequent in these tumors [70, 71]. Among the emerging entities [23], 
we discuss here only the ALK rearrangement-associated and TCEB1-mutated RCC. Although 
the former is an infrequent entity, its specific genetic change is also a promising therapeutic 
target, and ALK inhibitors are available for years [72]. The TCEB1 encodes the elongin C 
protein, which binds exactly the VHL protein to the E3 ubiquitin ligase [18]. The TCEB1-
mutated RCC harbors the bilateral loss of the TCEB1 gene, which is resulted by a 
chromosomal loss of 8q [73] and a nonsense mutation in the gene sequence [74]. So far, two 
hotspots were identified, and these are as follows Y79C/S/F/N and A100P, which interfere 
with VHL binding [74]. As we indicated above, a minority of all RCCs have genetic 
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susceptibilities [16, 17]. Since this thesis does not deal with familial renal cancers, these 
syndromes are briefly detailed in Table 3. 
 
Therapeutic Options for Renal Cell Carcinoma 
For almost one hundred years, the standard treatment of RCC remained unchanged; namely, 
the surgical removal of the entire tumor is the only option that can cure the patient [44]. The 
design of the surgery changed a lot because nowadays, the less invasive laparoscopic and 
nephron-sparing technics are preferred instead of the classic and opened radical nephrectomy 
[44, 75]. The simultaneous removal of the regional lymph nodes is not obligatory [75]. 
Unfortunately, imaging technics have no use for preoperative examinations, except for an 
angiomyolipoma; hence, to avoid unnecessary surgeries, especially for small or uncertain 
lesions, a core biopsy or a cytological sample should be taken from the tumor [75]. 
Syndrome Chromosome 
Location 
Gene Renal tumor(s) 
induced 
Other organs 
involved 
von Hippel-Lindau 3p25 VHL CCRCC CNS, pancreas, 
adrenal 
HLRCC 1q42 FH FH-deficient RCC Skin, uterus 
Hereditary PRCC 7q31 c-MET PRCC None 
Birt-Hugg-Dubé 17p11 FLNC ChRCC, LOT, HOT Skin, lung, GI 
SDH-associated 
familial renal cancer 
1p36 
11q23 
SDHB 
SDHD 
SDH-deficient RCC Ganglia, adrenal, 
GI 
Tuberous sclerosis 9q34 
16p13 
TSC1 
TSC2 
ESC RCC, CCRCC, 
ChRCC, AML 
Skin, CNS, lung, 
heart 
Sickle cell trait 11p15 HBB Medullary RCC None 
Cowden 10q22 PTEN PRCC, CCRCC Skin, breast etc 
Translocation of 
chromosome 3 
3p25 VHL CCRCC Unknown 
Table 3 List of hereditary renal tumors syndromes [16, 17].       
 
The treatment of metastatic RCC is still unsolved. A unifocal metastasis can be removed, but 
in general (the exceptions are not discussed here), there is no meaning of surgical treatment 
for multiple metastases [75]. Artificial embolization of the renal artery is performed only in 
inoperable cases having severe bleeding, and the procedure is not used for a preoperative 
induction of tumor shrinkage anymore [75]. Also, RCC is resistant to conventional chemo- 
and radiotherapy [44]. In clear cell RCC, the HIF1α overexpression activates many genes and 
results in increased protein synthesis, but in a therapeutic viewpoint, those genes and proteins 
are essential, which are responsible for angiogenesis [18]. The angiogenesis induced 
facilitates the survival of the tumor cells by providing them oxygen and nutrient supply; 
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nevertheless, these vessels are the main routes of metastatic dissemination, too. The 
inactivation of the angiogenesis-linked proteins by tyrosine kinase inhibitors (TKIs) results in 
a tumoral shrinkage and decreases metastatic potential [76]. The sunitinib is the most 
commonly used first-line drug for metastatic clear cell RCC patients, but others like axitinib 
or cabozantinib can be prescribed, too [75, 76]. In the case of progression, mTOR inhibition 
can be used as well [75]. For metastatic papillary RCC, an underlying c-MET mutation might 
be a possible target [77]. Concerning immunotherapy, regardless of the PD-L1 status, a 
combined PD1 and CTLA4 inhibition are commonly used for metastatic RCC patients [78]. 
Relying on the literature data, it seems immunotherapy is more effective in those cases that 
harbors severe genetic abnormalities [78]. 
 
Aims 
 
The diagnosis of clear cell RCC, papillary RCC, and chromophobe RCC is straightforward in 
most of the nephrectomy cases, but tumors with overlapping features can pose diagnostic 
difficulties. Also, from uncertain renal lesions and inoperable tumors, a biopsy sample is 
frequently taken. The proper diagnosis of such small and often fragmented material requires 
in-depth knowledge of histologic and immunohistochemical features of renal tumors to 
achieve a diagnostic certitude. However, before 2013, the knowledge on 
immunohistochemical features of RCC subsets was limited on reviews and expert opinions, 
and no unified recommendations had been published earlier. Besides, the diagnostic 
experience with the rare entities was minimal at the time of the introduction of the Vancouver 
classification. Taking into account the above statements, we composed the following aims for 
this thesis:  
To investigate the incidence, clinicopathological, and immunohistochemical characteristics of 
RCCs according to the 2016 WHO classification to expand our diagnostic expertise. 
To test the influence of grade, stage, resection line positivity, and the presence of a 
rhabdoid/sarcomatoid morphology, giant cells, and microscopic tumor necrosis on patient 
survival to prompt better patient care. 
To analyze the clinicopathological, immunohistochemical, and molecular features of two rare 
subsets, namely the clear cell papillary RCC and Xp11.2 translocation RCC, and lastly, to 
harvest data from Hungarian patients and to expand the literature data. 
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Materials and Methods 
 
General Aspects 
Histological Evaluation and Immunohistochemistry  
Here, the nephrectomy specimens enrolled were fixed in 10% neutral buffered formalin 
solution, and then, grossed according to the prevailing grossing protocols. The dissected 
tumor tissue was embedded in paraffin. Afterward, 4 µm thick sections were cut from the 
paraffin blocks, and they were stained with hematoxylin and eosin according to in-house 
protocols. The slides were reviewed, and the histological subtype was identified according to 
the 2016 WHO classification [16]. Further histological features were assessed, which are 
discussed below. The pathological stage was evaluated by using macroscopic and microscopic 
data, and it was amended according to the 8th edition of the AJCC/UICC TNM staging [28]. 
For immunohistochemistry, tissue microarray (TMA) blocks were created with a TMA 
Master (3DHISTECH) applying a 2 mm core diameter. One to four representative cores were 
then punched out from the donor blocks. Immunohistochemical stains together with the 
source and dilution of the antibodies used are summarized in Table 4. The epitope retrieval 
was performed for each antibody according to the manufacturer’s recommendations. The 
reactions were conducted using Autostainer (Dako). Afterward, slides were evaluated 
microscopically by estimating the proportion (%) of immunopositive cells. The scoring was 
performed in a semiquantitative manner, and staining in over 50% of the tumor cells, in 10 to 
50% of tumor cells, or less than 10% of the tumor cells, was interpreted as diffusely or focally 
positive or negative, respectively. For carbonic anhydrase 9 (CA9), only a membranous, 
while for TFE3 and TFEB, only nuclear labeling was treated as a positive. 
Antibody Clonality/Source/Clone Dilution 
CA9 rabbit polyclonal, Novus Biologicals 1/2000 
CK7 mouse monoclonal, Cell Marque, OV-TL 12/30 1/100 
CD10 mouse monoclonal, Biocare Medical, CM129 1/50 
AMACR rabbit polyclonal, Abcam 1/100 
MelanA mouse monoclonal, Labvision, A103 1/200 
HMB45 mouse monoclonal, Cell Marque, hmb-45 1/200 
TFE3 rabbit monoclonal, Cell Marque, mrq-37 1/100 
TFEB rabbit polyclonal, Bioss USA 1/50 
Cathepsin K mouse monoclonal, Abcam, 3f9 1/100 
Table 4 List and specificities of antibodies used.  
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Molecular Pathological Analysis 
Fluorescent in situ Hybridization 
FISH assays were carried out to detect either the loss of chromosome 3p and chromosome Y 
or gain of chromosome 7 and 17; furthermore, to identify a TFE3 gene rearrangement. Stated 
briefly, tissue sections were cut from the TMA blocks and deparaffinized. The assays were 
done using a VHL/cen3 probe (ZytoLight® SPEC VHL/CEN3 Dual Color Probe, Zytovision), 
centromeric probes for chromosome 7, 17 and Y (Cytocell) and a TFE3 probe (ZytoLight® 
SPEC TFE3 Dual Color Break-apart FISH Probe, ZytoVision) according to the 
manufacturer’s instructions. The slides were counterstained with 4, 6-diamidino-2-
phenylindole (Vysis) and scanned with a Pannoramic Midi slide scanner (3DHISTECH). The 
reactions were evaluated using a Pannoramic Viewer (3DHISTECH) in the following way. 
One hundred tumor cells from each case were examined and were compared with the same 
number of cells of the peritumoral tissue, which served as an internal control. The cutoff 
values of chromosomal gain and/or loss were set at the mean ±3SD of the corresponding 
control values, as done in previous studies [79]. The analysis of 3p deletion was also 
performed based on a published method [80]. The FISH reaction for TFE3 translocation was 
considered positive when over 10% of the neoplastic nuclei displayed a rearrangement [81]. 
VHL Gene Sequence and VHL Gene Promoter Region Hypermethylation 
Genomic DNA was extracted from tumor tissue using a High Pure PCR Template Preparation 
Kit (Roche). The VHL exons were amplified via specific primer pairs (Table 5). In the case of 
pathological mutation, the tumor-free renal tissue was analyzed as well. The PCR (25µl final 
volume) was conducted using 1µl of 10x buffer (Fermentas), 25 mM MgCl2, 2.5 mM dNTP, 
0.5 U/ µl Taq DNA polymerase (Fermentas), 10 pmol of each primer, and 50 ng of DNA. The 
reaction mixture was denatured for 5 min at 95°C and incubated for 39 cycles (denaturing for 
20 sec at 95°C, annealing for 30 sec at 59°C and extending for 30 sec at 72°C). The final 
extension was continued for 5 min at 72°C. The reaction products were checked for size and 
purity by agarose gel electrophoresis and then utilized for DNA sequencing. The sequencing 
primers were the same as those above, and a GenomeLAB DTCS - Quick Start Kit (Beckman 
Coulter) was used for DNA sequencing. The latter was carried out according to the 
manufacturer’s instructions using the GenomeLab GeXP Genetic Analysis System (Beckman 
Coulter). 
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VHL  Forward Primer (5’3’) Reverse Primer (5’3’) 
Exon 1a AGCGCGTTCCATCCTCTAC CTGCGATTGCAGAAGATGAC 
Exon 1b TACGGCCCTGAAGAAGACGG GGGCTTCAGACCGTGCTATC 
Exon 2 AGGACGGTCTTGATCTC GATTGGATAACGTGCCTGAC 
Exon 3 GTTGGCAAAGCCTCTTGTTC GAAGGAACCAGTCCTGTATC 
Table 5 Primer sequences for three exons of VHL used. Exon 1 was split into two parts.  
The methylation status of the VHL gene promoter region was determined using the 
methylation-specific PCR method. The extracted genomic DNA was modified using the 
EpiJET Bisulfite Conversion Kit (Thermo Fischer Scientific) and followed by PCR-based 
amplification with methylation-specific primer pairs (Table 6). The methylation status (non-
methylated or methylated) was determined by gel electrophoresis of the PCR products, as 
reported previously [82]. 
VHL  Forward Primer (5’3’) Reverse Primer (5’3’) 
Methylated TGGAGGATTTTTTTGCGTACGC GAACCGAACGCCGCGAA 
Unmethylated GTTGGAGGATTTTTTTGTGTATGT CCCAAACCAAACACAACAAA 
Table 6 Primer sequences for the methylation-specific PCR analysis of the VHL gene. 
 
Patient Follow-up and Statistical Methods 
The accessibility of the patient data was in harmony with ethical standards, and this analysis 
was conducted with the permission of the Medical Research Council (17489-4/2017/EKU). 
Demographical and clinical data were collected from the database management systems of 
Semmelweis University and the University of Szeged. Patient follow-up was based on the 
available clinical data such as radiological examinations, including ultrasound and computer 
tomography. The duration of follow-up was calculated from the date of the surgical treatment 
until the date of death or the last follow-up, and the RCC-related deaths were ascertained. The 
cancer-specific survival (CSS) was defined as the time from the surgery until death 
attributable to cancer or disease-related complications. The CSS was analyzed only in patients 
with clinical M0 disease determined by imaging modalities at the time of the surgery. CSS 
was estimated by using the Kaplan Meier method and compared among groups using log-rank 
tests. Deaths from causes other than RCC were censored. Univariate and multivariate Cox 
proportional hazards regression models were used to estimate the magnitude of the 
association of the RCC histological subtype with the patient outcome, as shown by the HR 
and 95% CI. Statistical analysis was performed with the SPSS software package. All p values 
were two-sided, and p > 0.05 was deemed significant. The recurrence-free survival rate was 
not evaluated in the present study. 
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Analysis of the Histological Subtypes and Prognostic Factors of RCC 
According to the 2016 WHO Renal Tumor Classification  
Here, a retrospective study was carried out at the Department of Pathology, University of 
Szeged. Between 1st January 1990 and 31st December 2015, 928 nephrectomies for RCC 
were evaluated. The ISUP grade, the surgical margin status, presence of necrosis, sarcomatoid 
differentiation, rhabdoid change, and multinucleated giant tumor cells were assessed. The 
highest grade occupying at least one low-power field determined the grade of the tumor. 
Sarcomatoid differentiation was noted if a high-grade spindle cell proliferation was observed 
(Figure 3a); also, a rhabdoid change was registered if the tumor cells showed the classic triad 
for rhabdoid cells; namely an excentric nucleus with a vesiculated chromatin structure, a 
prominent (cherry red) nucleolus and a cytoplasmic and eosinophilic inclusion (Figure 3b). 
The presence of these features was encountered if they occupied at least one low-power field. 
Additionally, the giant cells were not subcategorized. During the sampling of microscopic 
tumor necrosis, the extent of necrosis was not given a score.  
 
Analysis of the Clinicopathological, Immunohistochemical and 
Molecular Features of clear cell papillary RCC 
It was a three-institutional retrospective study, in which the Department of Pathology, 
University of Szeged, the 1st Department of Pathology and Experimental Cancer Research 
Institute and the 2nd Department of Pathology, Semmelweis University participated. From 
these departments, 2326 RCC samples were reexamined for clear cell papillary RCC-like 
 
Figure 3 The histological appearance of a sarcomatoid differentiation (a) and a rhabdoid 
change (b). Both images have a magnification factor of 200x.  
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tumors. The inclusion criteria were as follows, low-grade nuclei, the presence of any degree 
of tubulopapillary growth pattern of tumor cells with clear cytoplasm, linear arrangement of 
nuclei from the basal membrane, along with the presence of a leiomyomatous stroma. The 
diagnosis of clear cell papillary RCC was made if the formerly mentioned morphology 
together with characteristic immunophenotype (CK7- and CA9-positivity, negative CD10 or 
at most focal CD10-positivity, negative TFE3 and TFEB staining), along with the lack of 
genetic alterations indicating clear cell RCC (3p deletion, VHL mutation, VHL promoter 
hypermethylation), and papillary RCC (7 and 17 trisomy, loss of Y) were detected. Tumors 
with the same morphology, CK7, and CA9 coexpression, but with diffuse CD10-positivity or 
with altered VHL status were classed as clear cell RCC mimicking clear cell papillary RCC.    
 
Analysis of the Clinicopathological, Immunohistochemical and 
Molecular Features of Xp11.2 RCC 
Lastly, another retrospective study was completed which covered a large part of Hungary, 
because not just the departments mentioned above participated, but the Pathology Unit, Bács-
Kiskun County Teaching Hospital, Pathology Unit, Hetényi Géza County Hospital, Surgical, 
and Molecular Tumor Pathology Centre, National Institute of Oncology and the Department 
of Pathology, University of Pécs were involved as well. In total, 2804 RCC samples were 
reevaluated for translocation RCC. The diagnostic criteria for Xp11.2 RCC were the typical 
morphological pattern or moderate-to-strong nuclear positivity with TFE3 
immunohistochemistry or a positive TFE3 break-apart FISH analysis. 
 
Results 
Histological Subtypes of RCC and Prognostic Factors According to 
the 2016 WHO Renal Tumor Classification 
Based on the light microscopic appearance of the tumor and the results of immunostainings 
assessed, 83.5% of the samples were classified as clear cell RCC, 6.9% as papillary RCC, 
4.5% as chromophobe RCC, 2.3% as RCC unclassified, 1.1% as Xp11.2 translocation RCC, 
0.9% as clear cell papillary RCC, 0.4% as collecting duct carcinoma and 0.1% as mucinous 
tubular and spindle cell RCC. The clinicopathological features of the different subtypes are 
summarized in Table 7. Apart from chromophobe RCC, all these subsets were more common 
in men. The series comprised 28 extensively cystic carcinomas. Twenty-five cases were 
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reclassified as clear cell RCC, two as multilocular cystic clear cell renal cell neoplasm of low 
malignant potential, and one as clear cell papillary RCC. RCC occurred in 16 patients with 
end-stage kidney disease. The following morphotypes were encountered: clear cell on eleven 
occasions, papillary type 1 three times, and clear cell papillary on two occasions. Although 
the features of ACKD were observed in 9 end-stage kidneys with RCC, the histological 
evaluation did not lead to the suspicion of ACKD-associated RCC in any of these cases. As 
for synchronous tumors, clear cell RCC and papillary RCC type 1 in the same kidney were 
recorded in 2 patients, and clear cell RCC and oncocytoma in 1 patient. Bilateral clear cell 
RCC occurred in 3 patients, one of whom had end-stage kidney disease.  
Clear cell RCC 
The tumor was multifocal in 13 samples. Within the 522 (67.3%) low-grade carcinomas, the 
ISUP grade 2 cases were in the majority, while the ISUP grade 4 cases predominated within 
the 253 (32.7%) high-grade carcinomas. Among the high-grade carcinomas, the transition of a 
lower-grade carcinoma to a high-grade carcinoma was commonly observed; purely high-
grade “de novo” clear cell RCC was noted in 60 (7.7%) cases. As regards the high-grade 
features, giant tumor cells were most frequent (13%), followed by rhabdoid morphology 
(11%) and then sarcomatoid differentiation (6.4%). Four samples exhibited microscopic 
tumor necrosis in grade 1, 28 in grade 2, 65 in grade 3, and 124 in grade 4 group. 
Papillary RCC 
Our series consisted of 37 type 1 and 28 type 2 carcinomas, and all cases were unifocal. Type 
1 tumors had thin papillae lined usually by a single layer of tumor cells with minimal pale or 
clear cytoplasm and smaller, round nuclei appearing basophilic upon hematoxylin and eosin 
staining. In contrast, type 2 tumors displayed thicker papillae lined by tumor cells with 
abundant eosinophilic cytoplasm and larger, pleomorphic nuclei with a varying degree of 
nuclear pseudostratification. A combination of features of both histologic subtypes was noted 
in 5 samples, and these were assigned according to the predominant histological pattern. One 
type 1 and one type 2 carcinoma was negative for AMACR; however, because of the papillary 
appearance, the diffuse and strong CK7 reactivity and the TFE3-negativity of the tumor cells, 
the cases were assigned as papillary RCCs. The CK7 staining was negative in 2 cases of type 
1 carcinoma and 14 cases of type 2 carcinomas. Purely high-grade features were noted in 2 
cases of type 1 carcinoma and 17 cases of type 2 carcinoma. 
Chromophobe RCC 
Here, except for a single case, all tumors investigated were unifocal, and they mostly 
appeared to be low-grade. In 5 cases with marked oncocytic features, the possibility of 
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oncocytoma was excluded by the diffuse membranous and cytoplasmic CK7 reactivity of the 
tumor cells. Also, the morphology excluded SDH-deficient RCC, LOT along with HOT. 
Xp11.2 translocation RCC 
Two patients were younger than 45 years, while the eldest one was 72 years. All cases were 
uniformly negative for CA9 and CK7. The AMACR staining was negative in 7 cases, focally 
positive in 2 cases, and diffusely positive in 1 case. The labeling for TFE3 protein was diffuse 
in 8 samples, and focal in 2 samples. The FISH confirmed a TFE3 rearrangement in all cases. 
Clear cell papillary RCC 
This subset had the lowest median age. All tumors were in the pT1 stage. Also, two cases 
developed in end-stage renal disease. On light microscopy, marked angioleiomyomatous 
stroma was observed in 2 cases. The cup-shaped distribution of CA9 reactivity was seen in 3 
samples, box-shaped distribution in 5 samples, and the mixture of the patterns in one sample.  
Collecting duct RCC  
Four cases met the criteria of this subset. All were highly invasive with an advanced 
pathological stage. Histologically, high-grade cytological features, tubular or pseudotubular 
architecture with or without a desmoplastic stroma were observed. The tumor cells were 
diffusely positive for CK7 and were negative for CA9, AMACR, CD117, and TFE3. The 
Ulex europaeus staining revealed a diffuse positivity in 2 cases, a focal positivity in 1 case, 
and it was utterly negative in the remaining sample. 
Mucinous tubular and spindle RCC  
We observed a single case. The tumor was in stage pT1. The patient did not have any 
evidence of disease recurrence or metastatic dissemination during the follow-up of 7 months. 
RCC unclassified  
Seventeen out of 22 cases were high-grade carcinomas. One low-grade carcinoma was 
predominantly tubulopapillary, and the tumor cells had an optically clear cytoplasm. The CK7 
staining was negative, the AMACR staining revealed 80% positivity, and the CA9 reactivity 
appeared to be positive in 70% of the tumor cells. The TFE3 staining was negative. The other 
low-grade carcinoma resembled type 1 papillary carcinoma; however, the CK7 staining was 
negative, and the AMACR displayed only 50% reactivity.
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CRCC PRCC T1 PRCC T2 ChRCC Unclassified Xp11.2 RCC CCPRCC CDC MTSCC 
Number of cases (%) 
 
775 (83.5) 37 (3.9) 28 (3.0) 42 (4.5) 22 (2.3) 10 (1.1) 9 (0.9) 4 (0.4) 1 (0.1) 
Age (years) 
Median, 
range 
61, 25-84 62, 12-79 
62.5, 39-
78 
58, 17-74 63, 30-77 55, 15-72 51, 32-78 62, 49-69 68 
Male:female ratio 
 
1.5:1 3.1:1 2.1:1 0.82:1 2.6:1 2.3:1 1.25:1 1:1 female 
Right:left ratio 
 
1.09:1 0.89:1 1:1 1.21:1 0.69:1 0.25:1 1.25:1 0.33:1 right 
Size (mm) 
Median, 
range 
55, 10-
220 
43.5, 10-
150 
60, 9-170 50, 14-170 
86.5, 34-
173 
90, 25-160 22, 8-65 92, 55-140 40 
ISUP grade G1 158 3 0 18 0 1 8 0 1 
 
G2 364 29 7 21 5 3 1 0 0 
 
G3 99 2 15 3 8 0 0 0 0 
 
G4 154 3 6 0 9 6 0 4 0 
Microscopic tumor 
necrosis   
221 11 21 3 19 6 0 3 0 
Rhabdoid and/or 
sarcomatoid   
117 3 3 0 9 5 0 2 0 
Giant tumor cells 
 
105 3 1 0 2 0 0 0 0 
Surgical margin positivity 
 
37 1 2 0 0 2 0 2 0 
Postoperative tumor stage pT1a 216 16 7 13 1 2 8 0 1 
 
pT1b 147 7 3 9 3 1 1 0 0 
 
pT2a 49 5 4 6 1 1 0 0 0 
 
pT2b 18 3 1 8 1 0 0 0 0 
 
pT3a 297 6 10 6 13 2 0 2 0 
 
pT3b 16 0 0 0 2 1 0 0 0 
 
pT3c 9 0 0 0 0 0 0 0 0 
 
pT4 23 0 3 0 1 3 0 2 0 
Lymph node involvement  N1 29 2 5 0 4 2 0 1 0 
Distant metastases  M1 39 0 2 0 1 1 0 1 0 
TNM stage groupings  I 357 23 10 22 3 3 8 0 1 
 
II 63 7 5 14 2 1 0 0 0 
 
III 301 7 9 6 14 3 0 1 0 
 
IV 54 0 4 0 2 3 0 3 0 
Table 7 Clinicopathological features in different types of renal cell carcinoma. 
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Correlation between the morphotype and CSS  
Follow-up data sets were accessible for 804 patients (763 non-metastatic and 41 metastatic 
diseases at the time of surgery). One hundred thirty-one patients with clear cell RCC, three 
patients with type 1 papillary RCC, seven patients with type 2 papillary RCC, seven patients 
with RCC unclassified, six patients with Xp11.2 translocation RCC, and three patients with 
collecting duct carcinoma had died from an RCC-related cause. The median follow-up of 
these patients was 29 months (range 1-254 months), whereas the median follow-up for all 
survivors was 68 months (range 2-313 months). The CSS rates of histological types are 
shown in Figure 4. The 5-year 
CSS was significantly 
different between patients 
with clear cell RCC and with 
chromophobe RCC (p=0.021) 
or with RCC unclassified 
(p<0.001) or with Xp11.2 
translocation RCC (p<0.001), 
but not between patients with 
clear cell RCC and those with 
papillary RCC (p=0.39). 
Although the statistical 
significance in survival rates 
could not be calculated 
between clear cell RCC and clear cell papillary RCC or collecting duct carcinoma because of 
the limited number of cases in the latter entities, the Kaplan Meier curves leave no doubt that 
these entities represent an entirely different outcome. Among the 90 patients with non-
metastatic clear cell RCC at the time of nephrectomy and who died from an RCC-related 
cause, 18 patients received TKIs. Although the average survival time was longer in the treated 
group (5.9 years vs. 4.5 years), this did not affect CSS significantly (p=0.271); hence, the 
treatment of metastatic disease did not conflict with what the survival data tell us in Figure 4. 
Grade and microscopic tumor necrosis in clear cell RCC 
CSS rates according to the four-tiered ISUP grade and the two-tiered grade assessment are 
shown in Figure 5. When CSS according to the presence or absence of microscopic tumor 
necrosis was analyzed, the necrotic tumors exhibited a significantly poorer outcome than the 
non-necrotic tumors (p<0.001). When the presence or absence of tumor necrosis was tested in
 
Figure 4 Cancer-specific survival rates of 763 non-
metastatic patients with RCC based on histologic subtype. 
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patients with low-grade tumors vs. high-grade tumors (Figure 6), necrosis was associated with 
a significantly poorer outcome only in high-grade tumors. In univariate Cox proportional 
hazard analysis, the ISUP grade, TNM 
stage, tumor necrosis, giant tumor cells,  
rhabdoid/sarcomatoid change, and positive 
surgical margins all proved to be negative 
predictors of CSS. In multivariate Cox 
proportional hazards analysis, however, 
only the ISUP grade, TNM stage, and 
positive surgical margin turned out to be 
independent prognostic factors (Table 8). 
Subtypes and grade in papillary RCC 
The 5-year CSS rates in type 1 and type 2 
subtypes are shown in Figure 7. When the 
5-year CSS was calculated according to the 
ISUP grade, 100% was observed for grade 
1, 94% for grade 2, 74% for grade 3, and
 
Figure 5 Cancer-specific survival in clear cell RCC according to the ISUP grading 
system. A: The Kaplan Meier estimation did not reveal any difference in biological 
behavior between grade 1 vs. grade 2 tumors (p=0.550), and grade 3 vs. 4 tumors 
(p=0.226).  Grade 1 or grade 2 tumors displayed a significantly better survival rate among 
patients than grade 3 tumors (p<0.0001). B: When the grade 1 and 2 tumors were lumped 
together into low-grade carcinomas, and grade 3 and 4 tumors into high-grade carcinomas, 
the survival analysis revealed a significant difference between the two groups (p<0.0001). 
 
 
 
Figure 6 Kaplan Meier estimates in clear cell 
RCC according to low-grade (ISUP grade 
1+2) and high-grade (ISUP grade 3+4) 
assessment, and the presence or absence of 
microscopic tumor necrosis. The survival 
rates tended to be worse when tumor necrosis 
was present, but a difference attained a level 
of significance only in the high-grade 
subtypes (p=0.02). 
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33% for grade 4 samples, respectively. The 5-year survival rate was significantly better for 
patients with grade 2 tumors than for those with grade 3 tumors (p=0.011). The sample size in 
grade 1 tumors did not allow a comparison of survival rates between those with grade 1 and 
grade 3 tumors. However, there was no significant difference in survival rates between cases 
with grade 1 vs. grade 2 (p=0.696), and grade 3 vs. grade 4 (p=0.445); and, therefore, samples 
with grades 1 and 2, and grades 3 and 4 were merged to low-grade and high-grade categories. 
The 5-year CSS rates according to the two-tiered grading system exhibited a significant 
difference (Figure 7). In a Cox proportional hazard analysis, the ISUP grade and TNM stage, 
but not the morphotype, exerted a significant effect on the patient outcome (Table 9). 
Characteristic Hazard ratio CI 95% p value 
Univariate 
 ISUP grade 7.50 5.01-11.21 <0.001 
 TNM stage 2.54 2.04-3.15 <0.001 
 Surgical margin status 2.95 1.57-5.53 <0.001 
 
Microscopic tumor 
necrosis 
6.74 4.53-10.07 <0.001 
 
Rhabdoid/sarcomatoid 
change 
5.14 3.39-7.78 <0.001 
 Giant tumor cells 3.93 2.51-6.15 <0.001 
Multivariate 
 ISUP grade 4.33 2.36-7.95 <0.001 
 TNM stage 1.86 1.49-2.33 <0.001 
 Surgical margin status 2.61 1.39-5.2 0.003 
 
Microscopic tumor 
necrosis 
1.69 0.93-3.05 0.081 
 
Rhabdoid/sarcomatoid 
change 
0.96 0.57-1.61 0.896 
 Giant tumor cells 0.67 0.4-1.13 0.139 
Table 8 Cox regression analysis for cancer-specific survival rates in non-metastatic CCRCC. 
 
Characteristic Hazard ratio CI 95% p value 
Univariate 
 ISUP grade 4.12 1.75-9.69 0.001 
 TNM stage  2.8 1.36-5.78 0.005 
 WHO type  3.64 0.9-14.7 0.039 
 Surgical margin status  2.97 0.36-24.1 0.30 
 Microscopic tumor necrosis 1.89 0.5-7.15 0.34 
 Rhabdoid/sarcomatoid change 3.18 0.63-16.1 0.16 
 Giant tumor cells  2.38 0.29-19.4 0.41 
Multivariate 
 ISUP grade  2.77 1.01-7.53 0.046 
 TNM stage  2.33 103.5.28 0.042 
 WHO type  3.15 0.55-17.85 0.19 
 Surgical margin status  2.54 0.02-247.3 0.68 
 Microscopic tumor necrosis 1.74 0.33-9.16 0.58 
 Rhabdoid/sarcomatoid change 5.11 0.25-102.3 0.21 
 Giant tumor cells  0.36 0.003-49.1 0.68 
Table 9 Cox regression analysis for cancer-specific survival rates in non-metastatic PRCC. 
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Clinicopathological, Immunohistochemical and Molecular Features 
of Clear Cell Papillary RCC 
In this retrospective study, using the inclusion criteria, we retrieved 31 samples. All tumors 
coexpressed CK7 and CA9. The TFE3 and TFEB reactions were uniformly negative, and the 
CD10 and the AMACR reactions were negative in 27 and 30 cases, respectively. The FISH 
assays for papillary RCC, available in 27 cases, and deletion of chromosome 3p, available in 
29 cases, yielded negative results. The histomorphology, the results for VHL mutation and 
VHL methylation testing, and the immunophenotype confirmed 21 cases as clear cell papillary 
RCC and 10 cases as clear cell RCC. The main characteristics of the subsets are summarized 
in tables 10 and 11. 
General features of clear cell papillary RCCs  
Here, 21 tumors were examined, and the specimens were obtained from 12 females and 9 
males. The mean age was 60 years. Partial nephrectomy was performed in 4 patients and 
radical nephrectomy in 17 patients, and one tumor developed in a transplanted kidney. 
Twenty cases were incidental findings of imaging conducted for non-urological symptoms. 
All the tumors were solitary, and the mean size was 23 mm (with range 6 to 65 mm). 
Microscopic findings on clear cell papillary RCCs  
Each tumor was circumscribed, and at least one thin fibrous, or fibromuscular capsule was 
present, which contained smooth muscle in 13 tumors. A minimal infiltration of renal sinus 
fat was observed in case #3, but another invasive pattern was not seen at all. The dominant 
growth pattern was tubulo-acinar, with cyst formation in a continuum from microscopic to 
 
Figure 7 Kaplan Meier estimates in papillary RCC. A: The 5-year CSS rates in type 1 and 
type 2 subtypes were 92% and 65%, respectively (p=0.039). B: A significant difference 
was seen in survival rates between the low-grade (ISUP grade 1 + grade 2) and the high-
grade (ISUP grade 3 + grade 4) subtypes (p<0.001). 
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macroscopic cystic spaces in 12 samples. Also, a papillary architecture was observed in 14 
tumors and was detected mainly focally, except in one case where it was predominantly seen. 
Substantial areas with compact cell nests and trabeculae were seen in 11 samples. Foamy 
macrophages, psammoma bodies, prominent nucleoli, and necrosis were absent. Clear cell 
phenotype was characteristic that occasionally admixed with an eosinophilic morphology. 
The linear arrangement of nuclei, together with its orientation away from the basement 
membrane, was observed in 16 tumors. Stromal smooth muscle was found in 18 cases. For 
representative images of the features observed, see Figure 8. 
Immunohistochemical and molecular findings on clear cell papillary RCCs  
All exhibited a strong and diffuse CK7 expression. Immunoreaction for CA9 resulted in 
diffuse staining in 17 tumor samples and focal staining in 4 tumor samples. The “cup-shaped” 
pattern was detected in 17 cases, visible mainly in the tubular and cystic areas. CD10 was 
focally positive in two samples. In addition, weak granular, diffuse AMACR-positivity was 
noted in case #14. Representative images are in Figure 9. The mutation status of the VHL 
gene was investigated in 11 samples, and in case #12, a single nucleotide polymorphism 
(SNP) in the untranslated region (UTR) was found. The VHL gene methylation status was 
analyzed in 16 samples, and none of these harbored promoter region hypermethylation. 
General features of clear cell RCCs with diffuse CK7-positivity 
In this group, we analyzed 10 cases, and the mean age was 51 years, with 5 females and 5 
males. Tumor-related symptoms were registered in two patients. In case #23, a clear cell RCC 
(CA9 and CD10 positive; CK7 negative) was resected from the contralateral kidney two 
months after the first surgery. Additionally, in case #24, a metastatic perihilar lymph node 
was removed together with the tumorous kidney. The mean size of the tumors was 29 mm.  
Microscopic findings on clear cell RCCs with diffuse CK7-positivity 
The predominant growth pattern was a tubulo-acinar, followed by cystic, papillary, and solid. 
The tumors were composed of clear cytoplasm cells with focal eosinophilic change. Also, an 
apical linear nuclear arrangement was seen in 6 samples, and 2 cases contained a smooth 
muscle rich stroma. Infiltration of the renal vein, sinus, and perinephric fat was not observed. 
Immunohistochemical and molecular on clear cell RCCs with diffuse CK7-positivity 
There was coexpression of CK7 in a diffuse fashion and CA9 in a diffuse (8 cases) or focal 
fashion (2 cases). The cup-shaped distribution of CA9 was present in 6 cases. Diffuse CD10-
positivity was observed in case #23 and #24. The VHL gene mutation status was analyzed in 9 
samples, and in case #22, #23, and #31 a pathogenic mutation was identified that was not  
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Case Sex Age  
(y)  
ESRD Tumor-related 
symptoms 
Size 
(mm) 
AJCC 
Stage 
ISUP 
Grade 
Follow-up period 
(months) 
Progression Comment 
Clear cell papillary RCC 
1 M 68 No No 21 T1aNxMx 1 31 No  
2 M 57 No No 20 T1aNxMx 2 35 No  
3 M 64 No No 30 T3aNxMx 2 NA ND Sinus fat tissue infiltration 
4 F 68 No No 30 T1aNxMx 1 12 No  
5 M 84 ESRD No 10 T1aNxMx 1 1 No  
6 F 63 No No 8 T1aNxMx 2 46 No Ipsilateral oncocytoma 
7 F 81 No No 25 T1aNxMx 1 113 No  
8 F 78 No No 20 T1aNxMx 1 184 No  
9 M 56 ACKD No 10 T1aNxMx 1 85 No  
10 M 66 No No 11 T1aNxMx 1 3 No  
11 F 49 No No 38 T1aNxMx 1 10 No  
12 M 75 No No 65 T1bNxMx 2 80 No  
13 F 52 No No 25 T1aNxMx 2 158 No  
14 M 32 No No 8 T1aNxMx 1 101 No  
15 F 57 No No 6 T1aNxMx 1 NA ND  
16 F 30 ESRD No 8 T1aNxMx 1 86 No  
17 F 60 No Abdominal pain 22 T1aNxMx 1 3 No  
18 M 76 No No 10 T1aN0Mx 1 62 No Ipsilateral AML and papillary 
adenomas 
19 F 69 No No 13 T1aNxMx 1 8 No  
20 F 28 ESRD No 20 T1aNxMx 2 59 No Tumor in a graft kidney 
21 F 56 No No 30 T1aNxMx 1 NA ND  
Clear cell RCC with diffuse CK7-positivity 
22 F 41 No No 20 T1aNxMx 1 26 No  
23 F 44 No No 50 T1bN1Mx 1 36 No Lymph node metastasis 
24 M 37 No Hematuria 37 T1aNxMx 1 67 No Contralateral CCRCC 2 months 
later 
25 M 47 ACKD No 19 T1aNxMx 1 12 No  
26 F 53 No No 30 T1aNxMx 1 19 No  
27 F 69 No No 24 T1aNxMx 2 37 No  
28 M 69 No Lumbar pain 15 T1aNxMx 1 100 No Ipsilateral papillary adenoma 
29 M 40 No No 30 T1aNxMx 1 10 No  
30 F 51 No No 40 T1aNxMx 1 3 No  
31 M 61 No No 25 T1aNxMx 2 6 No  
M indicates, male; F, female, ESRD, end-stage renal disease; ACKD, acquired cystic kidney disease; NA, not available; ND, no data. 
Table 10 Clinicopathological features of the patients examined. 
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 Architecture of tumor volume (%) Immune profile (%) Molecular characteristics 
Case Tubular Papillary Cystic Solid LiN CK7 CA9 CA9 cup-shaped CD10 AMACR +7 +17 -Y -3p VHL mut VHL met 
Clear cell papillary RCC 
1 90 - - 10 No Diff Diff Yes Neg Neg - - - - wt ua 
2 88 2 - 10 Yes Diff Diff Yes Foc Neg - - - - wt - 
3 95 - - 5 Yes Diff Diff Yes Neg Neg nd nd nd nd nd nd 
4 59 1 20 20 Yes Diff Diff Yes Neg Neg - -  - wt - 
5 100 - - - Yes Diff Diff Yes Neg Neg - nd - - nd nd 
6 95 5 - - Yes Diff Diff Yes Foc Neg - -  - wt - 
7 44 5 50 1 No Diff Diff Yes Neg Neg - -  - wt - 
8 50 50 - - Yes Diff Diff Yes Neg Neg - -  - ua - 
9 80 10 - 10 No Diff Diff Yes Neg Neg - - - - wt - 
10 95 5 - - Yes Diff Diff Yes Neg Neg - - - - wt - 
11 50 40 10 - Yes Diff Diff Yes Neg Neg - -  - wt - 
12 50 - 50 - Yes Diff Diff Yes Neg Neg - - - - 5’UTR SNP# - 
13 - 80 20 - No Diff Diff Yes Neg Neg - -  - ua - 
14 80 10 10 - Yes Diff Diff Yes Neg Poz§ - - - - wt - 
15 - 20 80 - Yes Diff Diff No Neg Neg - -  - ua nd 
16 95 - - 5 Yes Diff Diff No Neg Neg - -   ua nd 
17 50 20 30 - No Diff Diff No Neg Neg - -  - wt - 
18 90 - 5 5 Yes Diff Foc Yes Neg Neg nd nd nd nd nd - 
19 45 1 50 4 Yes Diff Foc Yes Neg Neg - -  - nd - 
20 89 - 1 10 Yes Diff Foc Yes Neg Neg - -  - ua - 
21 85 1 5 10 Yes Diff Foc No Neg Neg - -  - ua - 
Clear cell RCC with diffuse CK7-positivity 
22 50 5 35 10 Yes Diff Diff Yes Neg Neg - -  - muta  + 
23 50 20 30 - Yes Diff Diff Yes Diff Neg nd nd  - mutb  nd 
24 10 50 20 20 No Diff Diff No Diff Neg - - - - 5’UTR SNP¶ - 
25 80 10 10 - No Diff Diff Yes Neg Neg - - - - wt + 
26 95 1 - 4 Yes Diff Diff Yes Neg Neg - -  - wt + 
27 20 10 70 - Yes Diff Diff Yes Neg Neg - -  - wt + 
28 40 - 60 - Yes Diff Diff Yes Neg Neg - - - - ua + 
29 20 40 40 - Yes Diff Diff No Neg Neg - - - - wt + 
30 30 - 20 50 No Diff Foc No Neg Neg - -  - wt + 
31 90 - - 10 Yes Diff Foc No Neg Neg - - - - mutc nd 
LiN indicates, linear nuclear arrangement from basement membrane; +7 and +17, trisomy of chromosome 7 and 17, respectively; -Y deletion of chromosome Y; -3p, deletion 
of chromosome 3p; VHL mut, von Hippel-Lindau gene mutation status; VHL met, von Hippel-Lindau gene methylation status; nd, not determined; wt, wild type; ua: 
unsuccessful analysis; 5’UTR SNP, single nucleotide polymorphism in 5’ untranslated region; diff: diffuse; foc: focal; neg: negative (less than or equal to 10%). §: weak 
granular positivity. #: exon 3 could not be amplified; ¶: exon1b could not be amplified, a: c.221T>A/p.V74N; b: c.625C>T/p.G209*; c: c.354_361delCTTCAGAGinsT. 
Table 11 Morphological, immunohistochemical, and molecular characteristics of the tumor cases examined. 
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present in the tumor-free renal parenchyma. The sequencing revealed an SNP without any 
clinical significance in case #24. The remaining five tumors analyzed harbored no genetic 
change. Also, the VHL gene promoter hypermethylation was tested in 8 cases, and 7 of them 
possessed promoter region hypermethylation.  
 
Figure 8 Histological features of the clear cell papillary tumors analyzed. The most 
characteristic architectural pattern was a branching tubular (a), in which the linear nuclear 
arrangement could be appreciated (insert in a). Solid areas were also encountered (b). A 
papillary pattern was frequently represented by papillary projections from cyst walls (c). 
Some polymorphism was seen, but prominent nucleoli were absent (d). Three tumors had 
a predominant papillary architecture (e). Myomatous stroma was seen in some cases (f). 
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Follow-up data of both patient group  
The median time was 52.5 months (with a range of 1 to 184 months) for clear cell papillary 
RCC patients and 31.6 months (with a range of 3 to 100 months) for clear cell RCC patients. 
Only three patients had no follow-up data, and two patients died in non-cancer-related causes. 
No tumor progression and recurrence was documented for the 26 surviving patients. 
 
Clinicopathological, Immunohistochemical and Molecular Features 
of Xp11.2 Translocation RCC 
Twenty-eight tumors proved to be Xp11.2 RCC among 2804 nephrectomies reviewed from 
the pathology departments listed above (0.99%). The diagnosis was later confirmed by 
immunohistochemistry in each case and by FISH analysis except for patient #11, #12, and 
#24. 
 
Figure 9 Immunohistochemical characteristics of the clear cell papillary RCC tumors 
analyzed. All cases displayed a diffuse and strong CK7-positivity (a), whereas CD10 was 
mainly negative, or only weekly and focally positive (b, asterisk: peritumoral kidney as an 
internal control). Extensive CA9 staining was also usually seen (c), the “cup-shaped” 
pattern could be appreciated mainly in the tubular areas (insert in c). AMACR was 
completely negative in most tumors (d, asterisk: peritumoral kidney as an internal control). 
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Clinical and follow-up data 
The clinicopathological findings are summarized in Table 12. Thirteen male and fifteen 
female patients were included in our cohort. The median age was 60 years (with range 8 to 
72). Three tumors occurred in children, and Wilms’ tumor was suspected in all the cases. The 
tumor produced symptoms in 9 patients. Also, the tumor was an incidental finding in 7 
patients. There were no underlying renal disorders in any patients in the affected kidney, but 
in patient #12, contralateral kidney agenesis was present. Among our patients, none had 
received chemotherapy or had had any previous malignant tumors. Nephrectomy was 
performed in each case except in three patients, who were treated with a partial nephrectomy 
because of the relatively small tumors (patient #7 and #8), and the absence of the contralateral 
kidney (patient #12). Follow-up information was accessible in 21 patients, and the mean 
follow-up time was 14 months (with range 2 months to 321 months). Regional lymph node or 
distant metastasis developed in 13 patients (9 had been discovered before surgery; 6 distant 
and 3 regional lymph node metastases). Seven patients died from cancer-related causes, and 
one patient died from a non-cancer-related cause. In patient #15, a regional lymph node 
metastasis developed after 12 months, so she was treated with retroperitoneal 
lymphadenectomy, and in the last follow-up, there were no signs of disease. Sixty months 
after the nephrectomy, patient #14 had multiple pulmonary, hepatic, and bone metastasis. He 
received tyrosine kinase and mTOR inhibitors until treatment failure. Also, in patient #27, 
multifocal vertebral metastasis developed. Currently, she is receiving TKI therapy, and she 
has stable disease. The remaining 11 patients were alive with no evidence of disease. 
Morphological findings on Xp11.2 RCCs 
All the tumors that were examined were unilateral and unifocal. The diameter of the tumors 
ranged from 15 mm to 160 mm, and the average was 78.5 mm. The invasion of the renal vein, 
sinus, and adipose capsule were observed in 7, 8, 6 cases, respectively. The predominant 
architectural appearance was a solid pattern, followed by a papillary pattern, while both a 
solid and papillary pattern was seen in a small proportion of the cases. The tumors were 
composed mostly of clear cells in 19 cases, mostly of eosinophilic cells in 7 cases, and a 
mixed eosinophilic and clear cell morphology was seen in two cases. Twenty-two cases had 
typical architecture with voluminous clear cytoplasm, nested, or papillary growth (Figure 10). 
The remaining 6 cases had a diverse morphology mimicking clear cell RCC except for patient 
5, whose tumor resembled a rhabdoid morphology and patient 6, whose tumor had an 
anaplastic carcinoma appearance (Figure 11). The presence of foamy cells, intracytoplasmic 
pigment, cholesterol clefts, psammoma bodies, and
  
 
3
6
 
Patient Age  
(y) 
Sex Symptoms† Side Size 
(mm) 
pT 
Stageǁ 
Node Status§ Metastasis or recurrence* Follow-up  
(mo) 
Status¶ 
1 52 M - L 70 4 - - - LTF 
2 69 M Incidental finding on CT L 50 1b - - - LTF 
3 47 M Hematuria, flank pain R 100 3b Neg Lung, Liver 2 DOD 
4 69 F Hematuria R 80 3a - Bone-U, Local R 53 DOD 
5 59 M Flank pain L 140 4 Pos - - LTF 
6 67 M Fatigue, subcostal pain L 160 4 Pos Liver, LN 2 DOD 
7 40 M - L 25 1a - None 127 NED 
8 15 F Palpable ventral mass L 55 1b - Lung, Vertebrae 14 DOD 
9 46 M Incidental finding L 100 2a Neg Local R 13 DOD 
10 72 F Flank pain L 140 3a - - 4 DOD 
11 21 F - R - 3a - - - LTF 
12 14 M - L - 1a - None 12 NCRD 
13 31 M Incidental finding on US L 55 1b - None 87 NED 
14 57 M - L 100 3a Neg Lung, Liver, Vertebrae  81 DOD 
15 40 F - R 110 3a - LN 65 NED 
16 50 F - R 45 1b - None 31 NED 
17 32 M Incidental finding B 15 1a - None 24 NED 
18 60 F Incidental finding - 16 1a - - - LTF 
19 66 F - R 60 1b Pos Adrenal gland - LTF 
20 32 M - R 20 1a Pos Liver - LTF 
21 17 F - R 35 1a - None 175 NED 
22 36 F Shoulder pain  R 120 3b - Scapula 13 AWD 
23 40 F Incidental finding R 41 1b - None 24 NED 
24 8 F Palpable ventral mass L 100 2b - - 321 NED 
25 54 F - R 120 3a Neg None 10 NED 
26 66 M Abdominal pain L 110 2b - None 4 NED 
27 51 F - R 65 1b - Vertebrae 3 AWD 
28 46 F Incidental finding L 110 3a Pos None 7 NED 
†Symptoms: including any tumor-related symptoms; incidental finding indicates a symptomless tumor; -, no data. ǁpT Stage: classification by AJCC 2016 TNM Staging 
System. §Node Status: nodal status at time of surgery; -, no lymph node was removed; Neg, negative; Pos, positive. A lymph node metastasis that developed during the 
follow-up period is listed in the ”Metastasis” column. *Metastasis: either found earlier or at the same time with the primary renal tumor, or during the follow-up period; 
Bone-U, bone, exact location is unknown; -, no data; R, recurrence; LN, lymph node. ¶Status: DOD, died of disease; LTF, patient is deceased, but lost to follow-up; NED, no 
evidence of disease; NCRD, not a cancer-related death; AWD, alive with disease; -, no data. 
Table 12 Clinicopathological features of the patients analyzed with Xp11.2 RCC. 
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necrosis was observed in 7, 4, 1, 11, and 17 cases, respectively. Most of the tumors had high-
grade features. A detailed summary of these microscopic findings can be found in Table 13. 
Immunohistochemical findings on Xp11.2 RCCs 
The results of the immunohistochemistry are summarized in Table 14. Three cases displayed 
positivity with CA9, although two of these were necrotic tumors. All the cases investigated 
were negative with CK7, while CD10 was strongly positive in 17 cases. AMACR was 
negative in 14 tumors, and a diffuse-to-focal positivity was seen in the remaining 14 cases. 
The diagnostic TFE3 reaction strongly labeled the nuclei in 26/28 cases, but Cathepsin K 
displayed positivity only in 6 tumors. MelanA was positive only in four cases, and HMB45 
showed a weak-to-diffuse positivity in three patients. 
 
Figure 10 Representative images of typical morphological features of Xp11.2 renal cell 
carcinomas. (a) A solid-nested pattern with an admixture of eosinophilic and clear cells. 
(b) An alveolar pattern populated by eosinophilic cells. Psammoma bodies are also 
present. (c) Papillary pattern with voluminous clear cells and psammoma bodies. (d) 
Occasionally the nuclei are near the apical surface of the cells, and they mimic clear cell 
papillary renal cell carcinoma. The arrows indicate the psammoma bodies. All the images 
have a magnification factor of 200x. 
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FISH findings on Xp11.2 RCCs 
The FISH reaction was performed in 25 cases because in patient #11, #12, and #24, the 
quality of the tumor tissue was not sufficient for a proper analysis. In 21 tumors, typical split 
signals were seen, while in patient #9 and #10, mostly a truncated signal pattern was 
observed. In patient #14, the signals were separated, but they were unusually close to each 
other. In patient #23 (a female), an entire break-point region was utterly absent. Hence, in this 
case, only one signal pair was detected in the nuclei of the tumor cells, while in the 
surrounding renal parenchyma, two unaffected signal pairs were present. In this case, the 
immunophenotype and histomorphology led us to classify the case as Xp11.2 RCC. 
Patient PP (%) SP 
(%) 
CCs 
(%) 
ECs 
(%) 
Foamy 
cells 
IP ChC PB Necrosis ISUP 
grade 
1 5 95 50 50 - - - - + 4 
2 40 60 30 70 + + - - - 2 
3 1 99 20 80 - - - - + 4 
4 50 50 90 10 - - - - + 2 
5 - 100 10 90 - - - - + 4 
6 - 100 5 95 - - - - + 4 
7 - 100 100 - - - - - - 1 
8 90 10 80 20 - - - - - 2 
9 50 50 70 30 - - - - + 4 
10 80 20 75 25 - - - - + 4 
11 95 5 90 10 + - - - - 3 
12 50 50 80 20 - - - + + 3 
13 100 - 100 - + - + + + 2 
14 10 90 60 40 - + - + - 2 
15 80 20 70 30 - + - - + 3 
16 90 10 75 25 + - - + - 3 
17 100 - 100 - - - - + - 2 
18 5 95 30 70 + - - + - 3 
19 10 90 80 20 - - - + + 2 
20 - 100 95 5 - - - + + 4 
21 - 100 30 70 - - - + - 2 
22 50 50 90 10 - - - - + 3 
23 - 100 80 20 + - - - + 3 
24 - 100 60 40 - - - - - 3 
25 80 20 30 70 + - - + + 3 
26 95 5 90 10 - + - - + 3 
27 100 - 50 50 - - - + - 3 
28 90 10 80 20 - - - - + 3 
PP, indicates papillary pattern; SP, solid pattern; CCs, clear cells; ECs, eosinophilic cells; IP, 
intracytoplasmic pigment; ChC, cholesterol clefts; PB, psammoma bodies; +, present; -, 
absent. 
Table 13 Histological findings of the Xp11.2 RCC tumors investigated 
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Pati
-ent 
CA9 CK7 CD10 AMACR MelanA HMB45 Cathepsin K TFE3 
IHC 
TFE3 
FISH 
1 N N D N N N N D + 
2 N N D N N N N D + 
3 N N N N N N N D + 
4 N N D D N N D D + 
5 N N D N N N N D + 
6 N N N N N N N D + 
7 N N D F N N N D + 
8 N N D D N N N D + 
9 N N N N N N N D + 
10 N N D N D N N D + 
11 N N D F N N F F NA 
12 N N D D N N N D NA 
13 N N D D N D N D + 
14 N N D D N F D D + 
15 N N N N D N N D + 
16 N N D D N N N D + 
17 N N D F N N N D + 
18 N N F D N N N F + 
19 N N F N N N N D + 
20 F N N N N N N N + 
21 N N D N N D D D + 
22 N N F D N N F D + 
23 N N N N N N N D + 
24 N N N N D N N F NA 
25 N N D D N N N F + 
26 N N D D F N F F + 
27 F N D N N N N N + 
28 F N F F N N N D + 
N, indicates negative; F, focally positive; D, diffusely positive; NA, data not available. 
Table 14 Immunohistochemical results of the Xp11.2 translocation RCCs analyzed.   
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Figure 11 Representative images of Xp11.2 renal cell carcinomas 
with unusual morphological features. (a) A tubular pattern 
resembling a low-grade clear cell carcinoma. (b) A solid pattern 
with foci of comedo-like necrosis. (c) A rhabdoid tumor-like 
pattern. (d) It has an anaplastic carcinoma appearance. All the 
images have a magnification factor of 200x. 
 
Figure 12 Representative images of the signal patterns seen in 
the tumors analyzed. (a) We see a pair of split signals (red and 
green arrows) in a male patient. (b) We see a pair of split signals 
(red and green arrows) in a female patient. Both images have a 
magnification factor 2000x. (c) The signals are separated (red and 
green arrows) but are unusually close to each other and normal 
fused (yellow arrows) signals are present in lymphocytes (patient 
14). (d) The loss of an entire break-point region that was 
observed in patient #23.  
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Discussion 
 
Histological Subtypes and Prognostic Factors of RCC According to 
the 2016 WHO Renal Tumor Classification 
Here, our investigation provided three new observations that complement or contradict the 
corresponding epidemiologic data of RCC. First, our series was characterized by a relatively 
low incidence of papillary RCC (6.9%). A literature survey on the incidence of RCC in 
European countries reveals a uniform occurrence rate of approximately 80% for clear cell 
RCC and a geographical variation for the occurrence of papillary RCC. In the series of 2333 
RCCs from Austria, 82.8% were clear cell, 10.9% papillary, 3% chromophobe, 0.3% 
collecting duct, and 3% unclassified [83]. In the study of 2197 small RCCs (≤ 4 cm) from 
Germany, the occurrence of clear cell, papillary, chromophobe, and unclassified histology 
was 84.4%, 10.3%, 4.5%, and 0.8%, respectively [84]. Also, a papillary RCC occurrence rate 
of 11% was observed in both Italy and Switzerland [85, 86]. In a recent publication from 
Denmark that focused on incidental renal neoplasms, 16% of the cases were diagnosed with 
papillary RCC [87]. The reason for the relatively low prevalence of papillary RCC in the 
Carpathian Basin remains unclear at present. Second, as regards the occurrence of the 
uncommon subtypes, clear cell papillary and Xp11.2 translocation RCC had a 0.9% and 1.1% 
prevalence, respectively. Our observation disagrees with those obtained in a much smaller 
series from the USA, claiming that clear cell papillary RCC should be the fourth most 
common (4.1%) RCC morphotype [88]. Regrettably, that study did not investigate the race of 
their patients, and hence a possible racial difference in the occurrence rate of clear cell 
papillary RCC should not be concluded. Collecting duct RCC or mucinous tubular and 
spindle cell RCC are very rare subtypes worldwide, and accordingly, these were the rarest in 
the present series. Third, a surprising finding was the lack of ACKD-associated RCC, which 
was said to be the most common RCC subtype in end-stage kidneys [89]. In our series, the 
most frequent subtype was clear cell RCC. In the evaluation of 43 RCCs in the native kidneys 
of patients who received kidney transplants in Budapest, Hungary, the predominant 
histological type was clear cell RCC [90]. In a multi-institutional study from Italy and Spain 
that analyzed the outcomes of RCC in patients with end-stage renal disease, clear cell RCC 
was similarly the most frequent subtype; and ACKD-associated RCC was not identified at all 
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[91]. Taken together, these findings do not support at all the statement that ACKD-associated 
RCC is the most common RCC subtype in end-stage renal disease [16]. 
Prognostic value of histologic subtypes of RCC 
Previous large sample sized studies focusing on the prognostic impact of clear cell, papillary, 
and chromophobe RCCs provided contradictory results. In the study of Patard et al. [92] on 
4063 RCC cases, the 5-year survival rates for localized clear cell, papillary, and chromophobe 
RCC were around 73.2% (in our cohort 83.4%), 79.4% (in our cohort 81%), and 87.9% (in 
our cohort 100%), respectively, but the histologic subtypes did not prove to be an independent 
prognosticator. By contrast, in the study of Leibovich et al. with 3062 RCCs, clear cell RCC 
subtype remained a significant predictor of cancer-specific death after adjustment for tumor 
size, stage, and grade [93]. In two studies examining 16957 patients together, the histologic 
subtype remained an independent prognostic factor in a multivariate model [94, 95].  
In the present study, the Kaplan Meier curves explored three, prognostically different groups.  
The first group, associated with an excellent prognosis, was formed by chromophobe RCC 
and clear cell papillary RCC. Chromophobe RCC has been described as usually a low-grade 
neoplasm with little tendency to progress and metastasize, and the reported 5-year survival 
rates range from 78% to 100% [96, 97]. Regarding clear cell papillary RCC, all our cases 
were kidney-limited and low-grade tumors, with no evidence of recurrence or metastatic 
disease in the follow-up period. Clear cell papillary RCC is discussed in more detail below.  
The second prognostic group, displaying a fair outcome (5-year survival rate around 80%), 
comprised papillary RCC and clear cell RCC. Type 1 tumors exhibited a pretty good, 92% 5-
year survival rate; these cancers were usually ISUP grade 1 or grade 2 tumors and not 
outgrown the kidney. In contrast, in type 2 tumors, the 5-year survival rate was just 65%; 
these cancers were predominantly present with ISUP grade 3 or grade 4 atypia and with 
locally advanced disease. The third group, displaying a bad prognosis, was observed with 
cases of unclassified RCCs, Xp11.2 translocation RCCs and collecting duct RCCs. More than 
half of our cases with unclassified RCC exhibited rhabdoid or sarcomatoid change or giant 
tumor cells, and the majority spread beyond the kidney; these features are predictors of a 
dismal prognosis. Xp11.2 translocation and collecting duct RCC have the worst prognosis 
reportedly, and our corresponding survival data was in accordance with this finding. 
Grade and microscopic tumor necrosis as prognostic parameters in clear cell RCC 
The survival analysis according to the ISUP grade provided two, statistically different 
subgroups, namely ISUP 1 plus 2 tumors, characterized by an excellent 5-year survival rate 
(96%) and ISUP 3 plus 4 tumors, characterized by a much worse survival rate (63%). 
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Delahunt et al. recently regraded 3017 clear cell RCCs from the Mayo Clinic according to the 
ISUP grades [39]. The difference in the survival rate between grade 1 and grade 2 groups did 
not attain a level of significance, and a similar situation was observed in our series. In contrast 
to our results, however, the survival rates of grade 3 vs. grade 4 cancers were significantly 
different. The reason for the different survival rates in the Szeged and the Mayo series appears 
to be the difference in the rates of grades: 21.5% and 9% for grade 1, 48.5% and 42% for 
grade 2, 12.2% and 40% for grade 3, and 17.6% and 9% for grade 4, respectively. The 
differences in the cases of the grade 1 and grade 3 cancers are significant, with many more 
grade 1 tumors in Szeged, and many more grade 3 tumors in Rochester. In our cohort, there 
was no significant difference in the survival rates between cases with grade 1 vs. grade 2, and 
grade 3 vs. grade 4 atypia and, therefore, samples with grades 1 and 2, and grades 3 and 4 
could be merged to low-grade and high-grade categories. Treating microscopic tumor necrosis 
as a prognostic parameter multivariate analyses yielded contradictory results [39, 98]. In our 
study, the multivariate model excluded microscopic tumor necrosis as an independent 
predictor of survival.  
Morphotype and grade as prognostic parameters in papillary RCC 
In our series, type 1 tumors exhibited a pretty good, 92% 5-year CSS rate. By contrast, the 5-
year CSS rate in type 2 tumors was only 65%. In a multivariate analysis, however, the ISUP 
grade and stage, but not the morphotype, affected patient outcome. Warrick et al. obtained 
similar results investigating correlations between tumor grade and histologic characteristics 
with clinical outcomes in 154 papillary RCCs [99]. In this study, no significant difference was 
found in survival rates between cases with grade 1 vs. grade 2, and grade 3 vs. grade 4 atypia, 
while the 5-year CSS rates in terms of the to the two-tiered grading system revealed a 
significant difference between the low-grade (95%) and high-grade cases (59%).  
Two-tiered grading for clear cell and papillary RCCs  
Since in clear cell RCC and papillary RCC there were no difference in survival in ISUP grade 
1 and grade 2, and ISUP grade 3 and grade 4 tumors, we have decided to start reporting these 
subsets as either “low-grade” (ISUP 1 or 2) or “high-grade” (ISUP 3 or 4). Our findings are 
supported by a recent report published by urologists, who simplified the four-tiered Fuhrman 
grading system into a low-grade/high-grade scheme, and the prognostic accuracy of the two 
schemes agreed perfectly in 2415 cases with clear cell RCC [100]. 
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Clinicopathological, Immunohistochemical and Molecular Features 
of Clear Cell Papillary RCC 
In this study, we focused on the discrimination of clear cell papillary RCC from other 
subtypes by applying the well-known immunohistochemical markers supplemented with 
molecular analysis that seeks to find chromosomal aberrations and VHL abnormalities. We 
made a formal diagnosis of clear cell papillary RCC when both the immunohistochemical and 
the genetic tests were in complete accordance with the histology. All the RCC subtypes with 
clear cell phenotype (e.g., TFE3 or TFEB translocation RCCs [16, 81], TCEB1-mutated RCC 
[73], RCC with 8p monosomy [101], RCC with prominent smooth muscle stroma (RCCSMS) 
[102-107] and RCC associated with von Hippel-Lindau syndrome) can exhibit a CCPRCC-
like morphology [108, 109], but clear cell RCC cases pose the most significant difficulty 
because this tumor is the most common and it also has some morphological similarities. We 
performed our case selection based on histological features suggestive of clear cell papillary 
RCC, and in all cases, the immunophenotype was in full harmony with this diagnosis except 
in two tumors displaying a CD10-positivity. In terms of genetics, 10 cases harbored a VHL-
related anomaly, so these were not treated as clear cell papillary RCCs. We accepted the view 
of Hes et al., who recommended not classifying cases with any VHL gene abnormality as 
clear cell papillary RCC [59]. Based on their approach, our tumors with altered VHL status 
were classified as clear cell RCC. After performing an immunohistochemical and molecular 
analysis, our selected cases were subdivided into two groups. These are clear cell papillary 
RCCs (21 cases), and clear cell RCCs with diffuse CK7-positivity (10 cases).  
Features of clear cell papillary RCC cases 
Here, the characteristic pattern was branching tubulo-acinar that was commonly accompanied 
by cyst formation, and the papillary pattern was a minor component. A similar observation 
was obtained by Aydin et al. [79] and Williamson et al. [110], hence the appellation 
“tubulopapillary” would perhaps be more apt, as was suggested by Aydin [79]. Linear nuclear 
arrangement away from the basement membrane is regarded as characteristic for clear cell 
papillary RCC [88]. We observed this phenomenon in 16 clear cell papillary RCCs and 7 
clear cell RCCs with diffuse CK7-positivity. Dhakal et al. examined 37 tumors with a 
morphologic overlap between clear cell papillary RCC and clear cell RCC features, and the 
linear nuclear arrangement was not seen exclusively in clear cell papillary RCC cases [111]. 
In another series of clear cell papillary RCCs, Williamson et al. noticed linear nuclear 
arrangement only in 24/55 cases [112]; therefore, it seems that linear nuclear arrangement is 
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an overemphasized phenomenon. Another finding considered specific for clear cell papillary 
RCC is the cup-shaped expression of CA9. We had four tumors with mostly a boxed-shaped 
staining pattern. Upon reviewing the literature, a cup-shaped expression involving 50% of 
tumor cells was reported by Rohan et al. in 3/9 cases [113]; and Dhakal et al. noted this 
pattern in 74% of their cases [111]; but Aydin et al. did not mention this feature at all in their 
36 cases [79]. Regarding the immunophenotype of our clear cell papillary RCCs, all tumors 
showed coexpression of CA9 and CK7. A focal CD10 and AMACR staining was encountered 
in 2 and 1 case, respectively. The former one raised the possibility of renal angiomyomatous 
tumor, which is currently considered as a morphologic variant of clear cell papillary RCC. 
Our clear cell papillary RCC group comprised 19 pT1a, 1 pT1b, and 1 pT3a cases, 
respectively. To best of our knowledge, this is the first reported case with infiltration outside 
of the kidney parenchyma. Also, in case #20, the tumor developed in a transplanted kidney. In 
a recently published review, RCCs arising in kidney grafts were summarized, but among the 
48 tumors described, not one was clear cell papillary RCC [114]. All our clear cell papillary 
RCC cases had an excellent clinical outcome, reinforcing the view that the carcinoma 
designation might be exaggerated [115].  
Features of clear cell RCCs with diffuse CK7-positivity 
A series of clear cell RCC with diffuse CK7-positivity was published a decade ago by Mai et 
al. [116]. Similar to our experiences, these samples were small-sized, and a non-metastatic 
course was recorded over a mean of a 3-year follow-up; and diffuse CK7-positivity was 
viewed as the indicator of indolent behavior [117]. Our results provide further 
clinicopathologic data on this rare subset of clear cell RCC. Accordingly, neither 3p deletion 
nor other chromosomal anomalies were present. The VHL gene sequence analysis revealed 
pathologic mutations in cases #22, #23, and #31. Since VHL mutations were not identified in 
the non-tumorous renal tissue, the possibility of VHL-disease-associated clear cell RCC was 
excluded. In seven samples, the histological and immunphenotypic data favored the diagnosis 
of clear cell papillary RCC; however, the presence of the VHL gene promoter 
hypermethylation abnormality led us to place these samples into the clear cell RCC group (in 
case #22 a coexisting VHL gene mutation was seen, too). After a search for methylation data, 
only two tumors analyzed were found in the literature out of 400 or so clear cell papillary 
RCCs [79, 118]. Methylation analyses performed by others in the future may validate our 
assumption that a VHL promoter hypermethylation is definitely not compatible with the 
diagnosis of clear cell papillary RCC. Every case was in pT1 stage, and there was no 
progression or recurrence. 
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Clinicopathological, Immunohistochemical and Molecular Features 
of Xp11.2 RCC 
Here, we reviewed 2804 nephrectomy cases and identified 28 Xp11.2 translocation RCCs. 
The incidence was low, and in our cohort, it was even lower than the literature data (0.99 vs. 
1-4%) [119]. We think that due to the relatively large number of patients studied, the analysis 
represents the exact frequency of Xp11.2 RCC in Hungary. These tumors were once regarded 
as childhood malignancies, but because of the significant overlapping features with clear cell 
and papillary RCC along with the limited cytogenetic data, some authors suggested that the 
exact frequency is underestimated in adults [120]. In our experience, 12 tumors occurred in 
less than 40 years, only four tumors affected children, and the oldest patient examined was 72 
years old. The previous use of chemotherapy and the association of translocation RCC was 
reported [121], but in our study, there was no patient with a prior history of malignancy. 
Discriminating Xp11.2 RCC from other subtypes of RCC is crucial for prognostic and 
predictive reasons. Recently, it was suggested that patients with Xp11.2 RCC might benefit 
from mTOR inhibitors [76]. The diagnosis relies on the morphological features, 
immunohistochemical findings, and molecular pathological analysis, but the latter is the most 
important because the detection of a TFE3 rearrangement is essential for a diagnosis of such a 
tumor. Xp11.2 RCC is usually diagnosed as a sizeable mass in the kidney. The mean size of 
our tumors (78.5 mm) was larger than that reported in earlier series [60, 120]. In our previous 
experience, only RCC unclassified and collecting duct carcinoma were larger than Xp11.2 
RCC. An invasion of the renal vein or the sinus is quite frequent; we noticed at least one of 
these in 12 patients. Metastatic spread to the regional lymph nodes or distant organs was 
observed in 32% cases; seven patients had the nephrectomy at the pM1 stage. Our 
observations on the rate of pT3/pT4 stage and the occurrence of metastasis are in accordance 
with the literature data [120]. This late-stage discovery might partly explain the generally 
poor outcome in Xp11.2 RCC. Microscopically, the predominant growth pattern is papillary, 
tubular, nested, and mixed, and a striking histological finding is the presence of the 
psammoma bodies [63, 122]. We saw a different distribution because the most frequent 
pattern was the solid one, followed by papillary and mixed architecture. Tumors were 
composed of mainly clear cells in 19 and eosinophilic cells in 7 cases. Also, the simultaneous 
presence of both cell types was noted in two cases.  Psammoma bodies were observed only in 
11 cases. Cases with atypical architecture can cause serious diagnostic difficulties; namely, 
the morphologic spectrum of Xp11.2 RCC is quite broad, and even urothelial cell carcinoma 
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mimicking translocation RCC was reported as well [81]. In our collection, we had a case 
mimicking anaplastic carcinoma and another with rhabdoid morphology. Some authors 
suggested that the specific translocation influences the histological appearance [123]. Xp11.2 
RCC is negative with CA9, CK7, and positive with CD10 and AMACR [16]. In our series, 
both CA9 and CK7 were entirely negative in almost every case except for CA9 in three 
samples. However, two of these tumors were extensively necrotic, and this is why we 
concluded that the staining was related to hypoxia of the tumor tissue. Diffuse CD10 labeling 
was noted in 60% of the cases, while AMACR-positivity was observed only in 50% of the 
tumors. The expression of MelanA and HMB45 is frequent in TFEB translocation RCC, but 
rare in Xp11.2 translocation RCC [63]. We saw a similar proportion; namely, MelanA and 
HMB45 were positive only in 4 and 3 tumors, respectively. For the diagnosis of Xp11.2 RCC, 
the TFE3 immunostaining is the most frequently used method. Earlier, the specificity and 
sensitivity of the immunohistochemistry were found to be 99.6%, and 97.5% [124], but in 
some cases, false-negative and false-positive results can be detected as well [125]. Argani et 
al. suspected that the shorter incubation time with the automated detection system made the 
TFE3 IHC more sensitive, while the specificity of the reaction decreased. For the false-
negative results, some authors showed that this might be caused by preanalytic factors (e.g., 
fixation time) or by the different analytical methodologies applied (e.g., poor-quality 
antibodies and inappropriate antigen retrieval) [81, 126]. There were only three tumors 
(patient #20, #24, and #27) with a TFE3-negativity, and the remaining cases displayed a 
diffuse and robust nuclear positivity. This is why, in our analysis, the sensitivity of the TFE3 
immunohistochemistry correlates with data in the earlier reports [124]. The cysteine protease 
Cathepsin K is a novel immunohistochemical marker for Xp11.2 RCC, although the 
expression depends on the fusion partner of the TFE3 gene, and this explains why it is 
expressed only in approximately 60% of Xp11.2 RCC [127, 128]. We had only six cases with 
Cathepsin K-positivity, which is slightly under the reported rate in the literature [81]. This 
difference might be related to different translocation partners.  
A TFE3 rearrangement can be identified by various methods, namely reverse transcription 
PCR, cytogenetic karyotyping, FISH analysis, and NGS. In the routine pathology service, the 
FISH test is the most commonly carried out technic [81, 129], but nowadays, NGS is more 
and more often used. NGS has a significant advantage because it can also detect the partner 
gene [130]; although, the influence on the prognosis of the fusion partner is unclear [125]. 
The TFE3 break-apart FISH probe was introduced in 2011, and it has since become an 
indispensable diagnostic tool for Xp11.2 RCC [81, 131]. However, the FISH analysis has its 
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limitations as well, because poor fixation, inappropriate hybridization, and/or extensive 
contamination with normal stromal cells can lead to negative results, but an optimized TFE3 
FISH is extremely useful in routine diagnosis and pathology consultation [129]. In our study, 
the diagnosis was supported by the TFE3 break-apart FISH analysis in 25 cases. The classic 
break-apart pattern was observed in 19 tumors, and a truncated signal pattern was noted in 2 
cases. In patient #14, the signals were unusually close to each other, and this phenomenon is 
indicative of intrachromosomal inversion, resulting in NonO-TFE3 gene fusion [62]. In a 
female patient, an entire break-point region was utterly missing from the cells due to an 
atypical translocation. In this case, the histomorphology and immunophenotype were 
concordant with Xp11.2 RCC. To our knowledge, this is the first report of such a signal 
pattern in Xp11.2 RCC.  
Some authors previously reported that Xp11.2 RCC had an indolent course [132-135]. 
Camparo et al. calculated a mortality rate of 13.6% for Xp11.2 RCC from their analysis and 
literature data, although the follow-up period was quite short [120]. In our cohort, the mean 
follow-up time was 14 months, and, in the meantime, 33% of the patients died from a cancer-
related cause. This indicates that Xp11.2 RCC has the same mortality rate as that calculated 
overall for RCC patients [92]. 
 
Conclusions 
 
In our first study, the distribution and prognostic features of RCC subtypes in 928 Hungarian 
Caucasian patients were analyzed. A relatively low incidence of papillary RCC was observed. 
Also, Xp11.2 RCC and clear cell papillary RCC exhibited frequencies of 1.1% and 0.9%, 
respectively. ACKD-associated RCC did not occur in a cohort of 16 end-stage kidney disease 
with RCC. Immunohistochemistry provides better subtyping of the cases, and in our hands, 
the panel of CA9, CK7, CD10, AMACR, and TFE3 is quite useful for the daily diagnostic 
service. For clear cell RCCs and papillary RCCs, low-grade (ISUP grade 1 plus 2) and high-
grade groups (ISUP grade 3 and 4) were assigned, and these groups were associated with 
different survival rates. Lastly, among the pathological prognostic factors in clear cell RCC, 
microscopic tumor necrosis did not prove to be an independent predictor of outcome. 
In the subsequent paper of ours, the immunophenotype and the genetic profile of 31 RCCs 
composed of clear cells, low-grade nuclei, and a tubulopapillary architecture were 
investigated. Twenty-one cases were classified as clear cell papillary RCC, and 10 as clear 
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cell RCC with diffuse CK7-positivity, and the following conclusions were drawn. First, clear 
cell papillary RCCs rarely exhibit a predominant papillary architecture, hence their name is 
misleading. Second, a linear nuclear arrangement away from the basement membrane and 
cup-like CA9-positivity is not essential feature. Third, the evidence for their malignant 
potential is still lacking. Fourth, RCCs with clear cell papillary RCC morphology, diffuse 
CK7-positivity, and with an altered VHL status do exist; and these tumors can be interpreted 
as clear cell RCC with diffuse CK7-positivity, and they can be differentiated from clear cell 
papillary RCCs only by carrying out molecular tests for the VHL status. Last but not least, the 
biological behavior of both clear cell papillary RCCs and clear cell RCCs with diffuse CK7-
positivity seems to be indolent with a favorable clinical outcome.   
Lastly, we studied 28 Xp11.2 RCC cases by descriptive light-microscopy, a panel of 
immunohistochemistry, and FISH tests. We had two tumors with a reasonably unusual 
morphology, one with an anaplastic carcinoma appearance and another with rhabdoid 
morphology. We observed a unique FISH pattern with the complete loss of the labeled break-
point region. The clinical follow-up was not complete for all the patients, but the mean 
follow-up period was more than 4 years, and it turned out that the prognosis of Xp11.2 RCC 
in adults is rather poor. 
 
To sum up, we gathered diagnostic experience in both common and rare RCC subsets. This 
knowledge makes us able to deal with in-house and consultation cases with certainty 
regardless of the specimen type. By analyzing the validated survival data, we identified 
prognostic groups according to the histological subsets, and we believe this will facilitate a 
better patient follow-up and treatment. The investigation of the patient outcomes in clear cell 
RCC led us to merge the ISUP grade 1 and 2 cases into low-grade and the ISUP grade 3 and 4 
cases into high-grade categories. We studied the clear cell papillary and Xp11.2 RCCs firstly 
in detail in Hungary. We estimated their incidence rate and provided clinicopathological, 
immunohistochemical as well as genetic data. Regarding the latter two, in our eyes, 
immunohistochemistry, along with the genetic tests, have an essential rule to discriminate 
against the overlapping and doubtful entities. Based on our experience, we created a summary 
table on the RCC subsets. 
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 CCRCC PRCC T1 PRCC T2 ChRCC CCPRCC Xp11.2 RCC CDC MTSCC 
Dominant 
cell type 
Clear Basophilic Eosinophilic Eosinophilic Clear 
Clear or 
eosinophilic 
Eosinophilic Basophilic 
Typical 
architecture 
Solid 
Papillary, 
rarely solid 
Papillary Solid Papillary Papillary 
Tubular or 
solid 
Tubular 
Other HE 
feature(s)  
Rich capillary 
network 
Foam cells, 
low-grade 
Foam cells, 
high- grade 
Perinuclear 
halos 
Leiomyomatous 
stroma 
Psammoma 
bodies 
Desmoplasia, 
inflammatory 
cells 
Mucin 
CA9 ++ - - - + (cup-shaped) +/- +/- - 
CK7 +/- ++ +/- ++ ++ - ++ ++ 
CD10 ++ + +/- - - ++ - + 
AMACR +/- ++ + - +/- + + ++ 
Other 
IHC(s) 
Vimentin + Vimentin + Vimentin + 
CD117 + 
Vimentin - 
Ø 
TFE3 +, 
MelanA +, 
HMB45 +, 
Cathepsin K + 
p63 -, CK20 -, 
GATA3 -, 
U. europeus + 
Vimentin + 
Genetics 
-3p, VHL 
mutation and 
hypermethylation 
c-MET 
mutation 
+7, +17, -Y 
Ø specific 
Chromosomal 
losses and 
gains 
No VHL-related 
anomaly 
TFE3 
rearrangement 
Ø specific 
Ø specific, 
but no +7, 
+17, -Y 
If the histological appearance, immunohistochemistry, and genetic test are inconclusive, but the tumor is positive for PAX8, furthermore, 
urothelial carcinoma along with metastasis was excluded, the case can be treated as an unclassified RCC. 
Table 15 A brief summary of the histological, immunohistochemical and genetic features of the RCC subsets experienced. 
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Abstract The morphotype and grade of renal cell carcinoma
(RCC) in 928 nephrectomies were reclassified according to
the 2016 WHO classification in order to analyze the distribu-
tion and outcomes of RCC subtypes in Hungary, to assess
whether microscopic tumor necrosis is an independent prog-
nostic factor in clear cell RCC, and to study whether a two-
tiered grading (low/high) for clear cell and papillary RCC
provides similar prognostic information to that of the four-
tiered ISUP grading system. 83.4% of the cohort were clear
cell, 6.9% papillary, 4.5% chromophobe, 2.3% unclassified,
1.1% Xp11 translocation, 1.1% clear cell papillary, 0.3%
collecting duct and 0.1% mucinous tubular and spindle cell
RCCs. RCC occurred in 16 patients with end-stage kidney
disease and none of them displayed features of acquired cystic
kidney disease-associated RCC. The 5-year survival rates
were as follows: chromophobe 100%, clear cell papillary
100%, clear cell low-grade 96%, papillary type 1 92%, clear
cell high-grade 63%, papillary type 2 65%, unclassified 46%,
Xp11 translocation 20%, and collecting duct 0%. The 5-year
survival rates in low-grade and high-grade papillary RCC
were 95% and 59%, respectively. In clear cell RCC, only the
grade, the stage and the positive surgical margin proved to be
independent prognostic factors statistically. Overall, papillary
RCC occurred relatively infrequently; microscopic tumor ne-
crosis in clear cell RCC did not predict the outcome indepen-
dently of the tumor grading; and the assignment of clear cell
and papillary RCCs into low-grade or high-grade tumors was
in terms of survival no worse than the ISUP grading.
Keywords Renal cell carcinoma . ISUP grading .
Microscopic tumor necrosis . Survival rates . Prognostic
factors
Introduction
The diagnostic categories of the 2016 WHO Renal Tumor
Classification was largely elaborated by the International
Society of Urological Pathology (ISUP) consensus conference
held in Vancouver, Canada in 2012 [1, 2]. The conference
made recommendations on classification, prognostic factors,
staging, and immunohistochemical and molecular evaluation
of renal cell carcinoma (RCC) [2–4]. 5 new entities were rec-
ognized. A new grading system was formulated with the in-
tention of replacing the Fuhrman’s grading system, which has
problems with the interpretation, validation and reproducibil-
ity [3, 5]. The incorporation of microscopic tumor necrosis in
clear cell RCC as a grading parameter was also proposed, but
it was agreed that further confirmatory studies were required
[6].
In the present study, the distribution and outcomes of RCC
morphotypes were analyzed in a set of Hungarian patients in
accordance with the 2016 WHO Renal Tumor Classification
in order to obtain reference data for the prevalence and cancer-
specific survival (CSS) of the traditional and new entities in
the south-eastern, non-industrialized region of Hungary, pop-
ulated entirely by Caucasians. Since the prognostic
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significance of microscopic tumor necrosis in clear cell RCC
has not yet been resolved, its presence relative to sarcomatoid/
rhabdoid differentiation, tumor grade, TNM stage and surgical
margin involvement was investigated using statistical
methods in order to see whether it has an independent impact
on CSS. Furthermore, the prognostic ability of a two-tiered
grading system for clear cell RCC and papillary RCC was
tested in order to conclude whether the simplification of the
four-tiered ISUP grading system to a two-tiered grading sys-
tem can be used in reporting RCCs.
Material and Methods
Review Process
Between 1st January 1990 and 31th December 2015, 843
radical and 85 partial nephrectomies for RCC were evaluated
in our department. The pathology reports and the hematoxylin
and eosin-stained slides were reviewed. Later the cases were
regraded according to the recommendations of the consensus
conference, and samples requiring immunostainings were se-
lected [4].
Immunohistochemical Support for the Diagnosis
Carbonic anhydrase IX, cytokeratin 7 (CK7), alpha-
methylacyl-CoA racemase, CD117, transcription factor
E3 (TFE3), HMB-45 and Ulex europaeus agglutinin
1immunostainings were applied in panels on tissuemicroarray
slides of samples taken (2 cores/case) from 474 cases
with overlapping lightmicroscopical features. The
histomorphology and the typical immunoprofile of the tumor
served to clarify the diagnosis [2, 4, 7–9]. If the
lightmicroscopical appearance and the immunoprofile of the
tumor did not allow the case to be assigned to the recognized
categories, unclassified RCC was diagnosed.
Fluorescence in Situ Hybridization (FISH) Assays
The histological diagnosis of Xp11 translocation RCC was
confirmed by ZytoLight® SPEC TFE3 Dual Color Break
Apart Probe [4], considered positive if more than 10% of the
tumor cells displayed a split signal. The diagnosis of clear cell
papillary RCCs was supported by the lack of chromosome 3p
loss (characteristic for clear cell RCCs), and the lack of triso-
my of chromosomes 7 and 17 and Y chromosome loss (feature
of papillary RCCs), looked for with appropriate probes
(Cytocell Chromosome 7, 17 and Y Alpha Satellite Probes,
ZytoLight® SPEC VHL/CEN3 Dual Color Probe) [10].
Pathological Features Evaluated
The ISUP nucleolar grade, the TNM stage amended according
to the seventh edition, the surgical margin status, and features
of nuclear pleiomorphism (i.e. sarcomatoid differentiation,
rhabdoid change, and multinucleated giant tumor cells) were
assessed [3, 11]. The highest grade occupying at least 1 high-
power field determined the grade of the tumor. During the
sampling of microscopic tumor necrosis in clear cell RCC,
the extent of necrosis was not given a score.
Estimation of CSS
The duration of follow-up was calculated from the date of the
surgical treatment to the date of death or the last follow-up.
The CSS was analyzed only in patients with clinical M0 dis-
ease determined by imaging modalities at the time of the sur-
gery. CSS was estimated by using the Kaplan-Meier method,
and compared among groups via log rank tests. Deaths from
causes other than RCC were censored. Univariate and multi-
variate Cox proportional hazard regression models served to
estimate the degree of the association of the RCC histological
subtype with the patient outcome, as shown by the HR and
95% CI. The statistical analyses were performed using the
SPSS software package (p > 0.05).
Results
The clinicopathological features of the different subtypes are
summarized in Table 1. The series comprised 28 extensively
cystic carcinomas. 25 cases were reclassified as clear cell
RCC, 2 as multilocular cystic clear cell renal cell neoplasm
of low malignant potential, and 1 as clear cell papillary RCC.
RCC occurred in 16 patients with end-stage kidney disease.
The following morphotypes were encountered: clear cell on
11 occasions, papillary type 1 on 3 occasions and clear cell
papillary on 2 occasions. Although the features of acquired
cystic kidney disease (ACKD) were observed in 9 end-stage
kidneys with RCC, the histological evaluation did not lead to
the suspicion of ACKD-associated RCC in any of these cases.
As for synchronous tumors, clear cell RCC and papillary RCC
type 1 in the same kidney were recorded in 2 patients, and
clear cell RCC and oncocytoma in 1 patient. Bilateral clear
cell RCC occurred in 3 patients, one of whom had end-stage
kidney disease.
Clear Cell RCC
Among the 253 (27%) high-grade carcinomas, the transition
of low-grade tumor cells to high-grade tumor cells was com-
monly observed; and purely high-grade clear cell RCC was
noted in 60 (7.7%) cases. 4 samples exhibited microscopic
690 L. Kuthi et al.
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Prognostic factors for renal cell carcinoma subtypes diagnosed 691
tumor necrosis in the grade 1 group, 28 in the grade 2 group,
65 in the grade 3 group, and 124 in the grade 4 group.
Papillary RCC
A combination of features of both histologic subtypes was
present in 5 samples and these were assigned according to
the predominant histological pattern. Type 1 carcinomas were
essentially of low-grade; while type 2 carcinomas were mostly
of high-grade
Chromophobe RCC
In 5 cases with predominantly eosinophilic cells, the possibil-
ity of oncocytoma was excluded by the diffuse membranous
CD117 and diffuse cytoplasmic CK7 reactivity of the tumor
cells, along with the positivity of the Hale colloidal iron
staining.
Xp11 Translocation RCC
The labeling for TFE3 protein was diffuse in 8 samples, and
focal in 2 samples. The FISH assay confirmed TFE3 gene
fusion in every case.
Clear Cell Papillary RCC
All of the tumors were in stage pT1. The FISH assay support-
ed the histopathological diagnosis in each case.
Collecting Duct RCC
All of the tumors were in an advanced stage, the main part of
the tumor being centered in the medulla. The Ulex europaeus
staining revealed diffuse positivity in 2 cases and focal posi-
tivity in 1 case.
Mucinous Tubular and Spindle RCC
The patient did not have any evidence of disease recurrence or
metastatic dissemination during the 15month follow-up period.
Unclassified RCC
The majority of cases proved to be high-grade carcinomas.
Correlation between the Morphotype and CSS
Follow-up data sets were accessible for 804 patients (763 non-
metastatic and 41 metastatic diseases at the time of surgery).
131 patients with clear cell RCC, 3 patients with type 1 pap-
illary RCC, 7 patients with type 2 papillary RCC, 7 patients
with unclassified RCC, 6 patients with Xp11 translocation
RCC, and 3 patients with collecting duct RCC had died from
an RCC-related cause. The median follow-up of these patients
was 29 months (range 1–254 months), whereas the median
follow-up for all survivors was 68 months (range 2–
313 months). The CSS rates of histological types are shown
in Fig. 1. The 5-year CSS was significantly different between
patients with clear cell RCC and with chromophobe RCC
(p = 0.021) or with unclassified RCC (p < 0.001) or with
Fig. 1 Cancer-specific survival
rates of 763 non-metastatic
patients with RCC based on
histologic subtype. A 100% 5-
year survival rate was observed
for clear cell papillary RCC and
chromophobe RCC. Clear cell
RCCs had an 83.4%, papillary
RCCs an 81%, unclassified RCCs
a 46%, Xp11 translocation RCCs
a 20%, and collecting duct RCCs
a 0% 5-year survival rate
692 L. Kuthi et al.
Xp11 translocation RCC (p < 0.001), but not between patients
with clear cell RCC and those with papillary RCC (p = 0.39).
Although the statistical significance in survival rates could not
be calculated between clear cell RCC and clear cell papillary
RCC or collecting duct RCC because of the limited number of
cases in the latter entities, the Kaplan Meyer curves leave no
doubt that these entities represent a quite different outcome.
Among the 90 patients with non-metastatic clear cell RCC
at the time of nephrectomy and who died from an RCC-related
cause, 18 patients received tyrosine-kinase inhibitors.
Although the average survival time was longer in the treated
group (5.9 years vs 4.5 years), this did not affect CSS signif-
icantly (p = 0.271); hence, the treatment of metastatic disease
did not conflict with what the survival data tell us in Fig. 1.
Grade and Microscopic Tumor Necrosis in Clear Cell
RCC
CSS rates according to the four-tiered ISUP grade and the
two-tiered grade assessment are shown in Fig. 2. A higher
TNM stage predicted a significantly poorer prognosis (see
Table 2). When CSS according to the presence or absence of
microscopic tumor necrosis was analyzed, the necrotic tumors
exhibited a significantly poorer outcome than the non-necrotic
tumors (p < 0.001; not shown). When the presence or absence
of tumor necrosis was tested in patients with low-grade tumors
vs high-grade tumors (Fig. 3), necrosis was associated with a
significantly poorer outcome only in high-grade tumors. In
univariate Cox proportional hazard analysis, the ISUP grade,
TNM stage, tumor necrosis, giant tumor cells, rhabdoid/
sarcomatoid morphology and positive surgical margins all
proved to be negative predictors of CSS. In multivariate Cox
proportional hazards analysis, however, only the ISUP grade,
TNM stage and positive surgical margin turned out to be in-
dependent prognostic factors (Table 2).
Subtypes and Grade in Papillary RCC
The 5-year CSS rates in type 1 and type 2 subtypes are shown
in Fig. 4. When the 5-year CSS was calculated according to
the ISUP grade, 100% was observed for grade 1, 94% for
grade 2, 74% for grade 3 and 33% for grade 4 samples, re-
spectively. The 5-year survival rate was significantly better for
patients with grade 2 tumors than for those with grade 3 tu-
mors (p = 0.011). The sample size in grade 1 tumors did not
allow a comparison of survival rates between those with grade
1 and grade 3 tumors. However, there was no significant dif-
ference in survival rates between cases with grade 1 vs grade 2
(p = 0.696), and grade 3 vs grade 4 (p = 0.445); and, therefore,
samples with grades 1 and 2, and grades 3 and 4 were merged
to low-grade and high-grade categories. The 5-year CSS rates
according to the two-tiered grading system exhibited a signif-
icant difference; namely 95% for low-grade tumors and 59%
for high-grade tumors (Fig. 4). In a Cox proportional hazard
analysis, the ISUP grade and TNM stage, but not the
Fig. 2 Cancer-specific survival in clear cell RCC according to the ISUP
grading system. a The Kaplan-Meier estimation did not reveal any
difference in biological behavior between grade 1 vs grade 2 tumors
(p = 0.550), and grade 3 vs 4 tumors (p = 0.226). Grade 1 or grade 2
tumors displayed a significantly better survival rate among patients than
grade 3 tumors (p < 0.0001). b When the grade 1 and 2 tumors were
lumped together into low-grade carcinomas, and grade 3 and 4 tumors
into high-grade carcinomas, the survival analysis revealed a significant
difference between the low-grade and high-grade groups (p < 0.0001)
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morphotype, exerted a significant effect on the patient out-
come (see Table 3).
Discussion
Distribution of RCC Morphotypes in Hungary
The incidence of RCC morphotypes is markedly influenced
by geographic location and race [12, 13]. In our study, the
incidence of entities reflects the situation in white people from
Central Eastern Europe, a fact which should be kept in mind
when tumor prevalences from countries populated with differ-
ent races are compared with those populated exclusively by
Caucasians. Our study provided three new observations which
complement or contradict the corresponding epidemiologic
data of the 2016 WHO Bblue book^.
First, our series was characterized by a a relatively low
incidence of papillary RCC (6.9%). A literature survey on
the incidence of RCC in European countries reveals a uniform
occurrence rate of approximately 80% for clear cell RCC and
a geographical variation for the occurrence of papillary RCC.
In the series of 2333 RCCs from Austria, 82.8% were clear
cell, 10.9% papillary, 3% chromophobe, 0.3% collecting duct,
and 3% unclassified [14]. In the study of 2197 small RCCs
(≤ 4 cm) fromGermany, the occurrence of clear cell, papillary,
chromophobe and unclassified histology was 84.4%, 10.3%,
4.5% and 0.8%, respectively [15]. Also, a papillary RCC oc-
currence rate of 11% was observed in both Italy and
Switzerland [16, 17]. In a recent publication from Denmark
that focused on incidental renal neoplasms, 16% of the cases
were diagnosed with papillary RCC [18]. The reason for the
relative low prevalence of papillary RCC in the Carpathian
Basin remains unclear at present.
Second, as regards the occurrence of the uncommon sub-
types, clear cell papillary and Xp11 translocation RCC had a
similar (1.1%) prevalence. Our observation disagrees with
those obtained in a much smaller series from the USA,
claiming that clear cell papillary RCC should be the fourth
most common (4.1%) RCC morphotype [19]. Regrettably,
Fig. 3 Kaplan Meier estimates in
clear cell RCC according to low-
grade (ISUP grade 1 and 2) and
high-grade (ISUP grade 3 and 4)
assessment, and the presence or
absence of microscopic tumor
necrosis. The survival rates
tended to be worse when tumor
necrosis was present. However,
the difference attained a level of
significance only in the high-
grade subtypes (p = 0.02)
Table 2 Cox regression analysis for cancer-specific survival rates in
non-metastatic clear cell RCC
Characteristic Hazard ratio CI 95% p value
Univariate
ISUP grade 7.50 5.01–11.21 <0.001
TNM stage 2.54 2.04–3.15 <0.001
Surgical margin status 2.95 1.57–5.53 <0.001
Microscopic tumor necrosis 6.74 4.53–10.07 <0.001
Rhabdoid/sarcomatoid change 5.14 3.39–7.78 <0.001
Giant tumor cells 3.93 2.51–6.15 <0.001
Multivariate
ISUP grade 4.33 2.36–7.95 <0.001
TNM stage 1.86 1.49–2.33 <0.001
Surgical margin status 2.61 1.39–5.2 0.003
Microscopic tumor necrosis 1.69 0.93–3.05 0.081
Rhabdoid/sarcomatoid change 0.96 0.57–1.61 0.896
Giant tumor cells 0.67 0.4–1.13 0.139
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that study did not investigate the race of their patients, and
hence a possible racial difference in the occurrence rate of
clear cell papillary RCC should not be concluded. Collecting
duct RCC or mucinous tubular and spindle cell RCC are very
rare subtypes worldwide, and accordingly, these were the rar-
est in the present series. Our series comprised 28 extensively
cystic carcinomas, and the vast majority of cases turned out to
be cystic clear cell RCC [10, 20]. Tubulocystic RCC did not
occur in our cohort.
Third, a surprising finding was the lack of ACKD-
associated RCC, which was said to be the most common
RCC subtype in end-stage kidneys [21]. In our series, the most
frequent subtype was clear cell RCC. In the evaluation of 43
RCCs in the native kidneys of patients who received kidney
transplants in Budapest, Hungary, the predominant histologi-
cal type was clear cell RCC [22]. In a multi-institutional study
from Italy and Spain that analyzed the outcomes of RCC in
patients with end-stage renal disease, clear cell RCC was sim-
ilarly the most frequent subtype; and ACKD-associated RCC
was not identified at all [23]. In a recent study of 181 patients
with end-stage renal disease and RCC from South Korea,
tumor histologic type was clear cell in 63%, papillary in
17%, chromophobe in 5%, clear cell papillary in 2.8% and
ACKD-related in 6.1% of the cases [24]. Taken together, these
findings do not support at all the statement that ACKD-
associated RCC is the most common RCC subtype in end-
stage renal disease [1, 23].
Prognostic Value of Histologic Subtypes of RCC
Previous large sample sized-studies focusing on the prognos-
tic impact of clear cell, papillary and chromophobe RCCs
provided contradictory results. In the study of Patard et al.
[25] on 4063 RCC cases, the 5-year survival rates for localized
clear cell, papillary, and chromophobe RCC were around
73.2% (in our cohort 83.4%), 79.4% (in our cohort 81%),
and 87.9% (in our cohort 100%), respectively. However, when
histologic subtypes, TNM stage, Furhman grade, and Eastern
Cooperative Oncology Group performance status were sub-
jected to a multivariate analysis, the histologic subtypes did
Fig. 4 Kaplan Meier estimates in papillary RCC. a The 5-year CSS rates
in type 1 and type 2 subtypes were 92% and 65%, respectively
(p = 0.039). b A significant difference was seen in survival rates
between the low-grade (ISUP grade 1 + grade 2) and the high-grade
(ISUP grade 3 + grade 4) subtypes (p < 0.001)
Table 3 Cox regression analysis for cancer-specific survival rates in
non-metastatic papillary RCC
Characteristic Hazard ratio CI 95% p value
Univariate
ISUP grade 4.12 1.75–9.69 0.001
TNM stage 2.8 1.36–5.78 0.005
WHO type 3.64 0.9–14.7 0.039
Surgical margin status 2.97 0.36–24.1 0.30
Microscopic tumor necrosis 1.89 0.5–7.15 0.34
Rhabdoid/sarcomatoid change 3.18 0.63–16.1 0.16
Giant tumor cells 2.38 0.29–19.4 0.41
Multivariate
ISUP grade 2.77 1.01–7.53 0.046
TNM stage 2.33 103.5.28 0.042
WHO type 3.15 0.55–17.85 0.19
Surgical margin status 2.54 0.02–247.3 0.68
Microscopic tumor necrosis 1.74 0.33–9.16 0.51
Rhabdoid/sarcomatoid change 5.11 0.25–102.3 0.28
Giant tumor cells 0.36 0.003–49.1 0.68
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not prove to be an independent prognosticator. By contrast, in
the study of Leibovich et al. on 3062 RCCs, clear cell RCC
subtype remained a significant predictor of cancer specific
death after adjustment for tumor size, stage and grade [26].
Capitanio et al. assessed the magnitude of the effect of histo-
logic subtype on cancer-specific mortality in 11,618 nephrec-
tomies because of RCC [27]. In a multivariate model
predicting cancer-specific mortality, histologic subtype
remained an independent predictor. In the study of 5339
Italian patients, the histologic subtype was shown to be a
predictive variable for cancer-specific mortality in a multivar-
iate analysis [16].
In the present study, the Kaplan Meier curves explored
three, prognostically different groups.
The first group, associated with an excellent prognosis, was
formed by chromophobe RCC and clear cell papillary RCC.
Chromophobe RCC has been described as usually a low-
grade neoplasm with little tendency to progress and metasta-
size; and the reported 5-year survival rates range from 78% to
100% [28, 29]. Predictors of progression include the micro-
scopic tumor necrosis, sarcomatoid change and stage of the
tumor [28, 30]. Although chromophobe RCCs should not be
graded at the moment, all our cases lacked high-grade
features, and only 3 out of 42 displayed microscopic
tumor necrosis; and the majority of cases were limited
to the kidney, features which help explain the observed
excellent survival rate. Regarding clear cell papillary
RCC, all our cases were kidney-limited and low-grade
tumors, with no evidence of recurrence or metastatic
disease in the follow-up period. Similar features have
been reported with this subtype all over the world.
Because of the excellent outcome data, this entity was
recently suggested to be renamed as clear cell papillary
neoplasm of low malignant potential [31].
The second prognostic group, displaying a fair outcome (5-
year survival rate around 80%), comprised papillary RCC and
clear cell RCC. In a recent study investigating correlations
between tumor grade and histologic characteristics with clin-
ical outcome in 154 cases of papillary RCC, the histologic
subclassification was of relative prognostic significance
[32]. Our findings turned out to be quite similar. Type 1
tumors exhibited a pretty good, 92% 5-year survival
rate; morphologically these cancers were usually mani-
fested with ISUP grade 1 or grade 2 atypia and were
usually presented with kidney-limited disease. In con-
trast, in type 2 tumors the 5-year survival rate was just
65%; morphologically these cancers were predominantly
present with ISUP grade 3 or grade 4 atypia and almost
half of the tumor cases had grown outside the kidney at
the time of the surgical removal. In Cox proportional
hazard analysis, the ISUP grade and TNM stage, but
not the morphotype, had an effect on the patient out-
come. In an Austrian study on 88 type 1 and 89 type 2
papillary RCCs, the presence and extent (>20%) of his-
tological tumor necrosis were demonstrated to be nega-
tive prognostic factors in type 1, but not in type 2
carcinoma [33, 34]. Since the sample size in our series
was much smaller, we could not investigate microscopic
tumor necrosis in isolation.
The third group, displaying a bad prognosis, was ob-
served with cases of unclassified RCCs, Xp11 translo-
cation RCCs and collecting duct RCCs. More than half
of our cases with unclassified RCC exhibited rhabdoid
or sarcomatoid change or giant tumor cells, and the
majority spread beyond the kidney; these features are
predictors of a dismal prognosis. Xp11 translocation
RCC and collecting duct RCC have reportedly the worst
prognosis, and the corresponding survival data in our
series was in complete accordance with this finding.
Grade and Microscopic Tumor Necrosis as Prognostic
Parameters in Clear Cell RCC
The survival analysis according to the ISUP grade provided
two, statistically different subgroups, namely ISUP 1 plus 2
tumors, characterized by an excellent 5-year survival rate
(96%), and ISUP 3 plus 4 tumors, characterized by a much
worse survival rate (63%). Delahunt et al. recently regraded
3017 clear cell RCCs from the Mayo Clinic according to the
ISUP grades [6]. The difference in the survival rate between
the grade 1 and grade 2 groups did not attain a level of signif-
icance, and a similar situation was observed in our series. In
contrast to our results, however, the survival rates of grade 3
vs grade 4 cancers were significantly different. The reason for
the different survival rates in the Szeged and the Mayo series
appears to be the difference in the rates of grades: 21.5% and
9% for grade 1, 48.5% and 42% for grade 2, 12.2% and 40%
for grade 3, and 17.6% and 9% for grade 4, respectively. The
differences in the cases of the grade 1 and grade 3 cancers are
significant, with many more grade 1 tumors in Szeged, and
many more grade 3 tumors in Rochester. In our cohort, there
was no significant difference in the survival rates between
cases with grade 1 vs grade 2, and grade 3 vs grade 4 atypia
and, therefore, samples with grades 1 and 2, and grades 3 and
4 could be merged to low-grade and high-grade categories.
This is an important finding.
Treating microscopic tumor necrosis as a prognostic pa-
rameter multivariate analyses yielded contradictory results
[6, 35, 36]. In our study, the multivariate Cox model excluded
microscopic tumor necrosis as an independent predictor of
survival. Nevertheless, we do not rule out the possibility that
a larger sample size might lead to a different result because
when Delahunt et al. incorporated microscopic tumor necrosis
into the ISUP grading system, a significant difference in sur-
vival between each of the grades for clear cell RCC was ob-
served [6].
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Morphotype and Grade as Prognostic Parameters
in Papillary RCC
Papillary RCC is a heterogeneous disease with two histologic
subtypes and variations in patient outcomes. Genetically, type
1 tumors are usually associated with alterations in the MET
pathway, while type 2 tumors have at least three different
pathways, among which CDKN2A loss or fumarate hydratase
gene mutation are associated with a low survival rate [37].
Unfortunately, any correlation between the main driver genet-
ic events and the grade of the tumor was not sought in that
study.
In our series, type 1 tumors exhibited a pretty good, 92% 5-
year survival rate. By contrast, the 5-year survival rate in type
2 tumors was only 65%. In a Cox proportional hazard analy-
sis, however, the ISUP grade and TNM stage, but not the
morphotype, had an effect on patient outcome. Similar results
were obtained in a recent publication investigating correla-
tions between tumor grade and histologic characteristics with
clinical outcome in 154 cases of papillary RCC [33]. In the
present study, no significant difference was found in survival
rates between cases with grade 1 vs grade 2, and grade 3 vs
grade 4 atypia, while the 5-year CSS rates outcome in terms of
the to the two-tiered grading system revealed a significant
difference between the low-grade (95%) and high-grade cases
(59%).
Two-Tiered Grading for Clear Cell and Papillary RCCs
Since in clear cell RCC and papillary RCC there were no
difference in survival in ISUP grade 1 and grade 2, and
ISUP grade 3 and grade 4 tumors, we have decided to start
reporting these subsets as either Blow-grade^ (ISUP 1 or 2) or
Bhigh-grade^ (ISUP 3 or 4). We think that this simplification
helps the urologists and oncologists to better understand the
pathology report. Our findings are supported by a recent re-
port published by urologists, who simplified the four-tiered
Fuhrman grading system into a low-grade/high-grade scheme
and the prognostic accuracy of the two schemes agreed per-
fectly in 2415 cases with clear cell RCC [38].
Morphological Prognosticators and Postoperative
Management
The updated assessment of tumor grade, TNM stage, and his-
tological subtype is mandatory since these variables can serve
as selection criteria for clinical trials investigating periopera-
tive management of localized kidney cancer [39]. In the
ARISER study on organ confined clear cell RCC, for exam-
ple, high-risk patients were defined on the basis of TNM stage
and nuclear grade, and these patients received adjuvant
girentuximab immunotherapy postoperatively, unfortunately
without clinical benefit [40].
Summary and Conclusions
The distribution and prognostic features of RCC subtypes in
928 Hungarian Caucasian patients were analyzed after a revi-
sion of cases according to the 2016 WHO Renal Tumor
Classification. A relatively low incidence of papillary RCC
was observed. Also, Xp11 translocation RCC and clear cell
papillary RCC exhibited incidences of 1.1% and 1.1%, re-
spectively. ACKD-associated RCC did not occur in a cohort
of 16 end-stage kidney disease with RCC. In clear cell RCC
and papillary RCCs, low-grade (ISUP grade 1 plus 2) and
high-grade groups (ISUP grade 3 and 4) were assigned, and
these groups were associated with statistically different sur-
vival rates. Lastly, among the pathological prognostic factors
in clear cell RCC, microscopic tumor necrosis did not prove to
be an independent predictor of outcome.
Acknowledgment This study was supported by TÁMOP-4.2.2. A-11/
1/KONV-2012-0. Earlier, some findings of the study were presented in a
shortened form at the European Congress of Pathology, in Belgrade,
Serbia, 2015
References
1. Moch H, Humphrey PA, Ulbright TM, Reuter VE (2016) WHO
classification Tumours of the urinary system and male genital or-
gans. International Agency for Research on Cancer, Lyon
2. Srigley JR, Delahunt B, Eble JN et al (2013) The International
Society of Urological Pathology (ISUP) Vancouver classification
of renal neoplasia. Am J Surg Pathol 37:1469–1489
3. Delahunt B, Cheville JC, Martignoni G et al (2013) The
International Society of Urological Pathology (ISUP) grading sys-
tem for renal cell carcinoma and other prognostic parameters. Am J
Surg Pathol 37:1490–1504
4. Reuter VE, Argani P, Zhou M, Delahunt B, Members of the ISUP
Immunohistochemistry in Diagnostic Urologic Pathology Group
(2014) Best practices recommendations in the application of immu-
nohistochemistry in the kidney tumors: report from the
International Society of Urologic Pathology consensus conference.
Am J Surg Pathol 38:e35–e49
5. Steffens S, Janssen M, Ross FC et al (2014) The Fuhrman grading
system has no prognostic value in patients with nonsarcomatoid
chromophobe renal cell carcinoma. Hum Pathol 45:2411–2416
6. Delahunt B, McKenney JK, Lohse CM, Leibovich BC, Thompson
RH, Boorjian SA, Cheville JC (2013) A novel grading system for
clear cell renal cell carcinoma incorporating tumor necrosis. Am J
Surg Pathol 37:311–322
7. Tan PH, Cheng L, Rioux-Leclercq N et al (2013) Renal tumors:
diagnostic and prognostic biomarkers. Am J Surg Pathol 37:1518–
1531
8. Genega EM, Ghebremichael M, Najarian R et al (2010) Carbonic
anhydrase IX expression in renal neoplasms: correlation with tumor
type and grade. Am J Clin Pathol 134:873–879
9. Gupta R, Billis A, Shah RB et al (2012) Carcinoma of the collecting
ducts of Bellini and renal medullary carcinoma: clinicopathologic
analysis of 52 cases of rare aggressive subtypes of renal cell carci-
noma with a focus on their interrelationship. Am J Surg Pathol 36:
1265–1278
Prognostic factors for renal cell carcinoma subtypes diagnosed 697
10. Williamson SR, Cheng L (2016) Clear cell renal cell tumors: not all
that is Bclear^ is cancer. Urol Oncol 34:292.e17–292.e22
11. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classifi-
cation of malignant tumors, 7th edn. Wiley-Blackwell, Oxford
12. Tarabeia J, Kaluski DN, BarchanaM, Dichtiar R, GreenMS (2010)
Renal cell cancer in Israel: sex and ethnic differences in incidence
and mortality, 1980-2004. Cancer Epidemiol 34:226–231
13. Lipworth L, Morgans AK, Edwards TL et al (2016) Renal cell
cancer histologic subtype distribution differs by race and sex.
BJU Int 117:260–265
14. Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner
K, Pummer K, Zigeuner R (2012) Renal cell carcinoma stage mi-
gration in a single European Centre over 25 years: effects on 5- and
10-year metastasis-free survival. Int Urol Nephrol 44:997–1004
15. Steffens S, Junker K, Roos FC et al (2014) Small renal cell
carcinomas–how dangerous are they really? Results of a large mul-
ticenter study. Eur J Cancer 50:739–745
16. Novara G, Ficarra V, Antonelli A et al (2010) Validation of the 2009
TNM version in a large multi-institutional cohort of patients treated
for renal cell carcinoma: are further improvements needed? Eur
Urol 58:588–595
17. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ
(2000) Prognostic utility of the recently recommended histologic
classification and revised TNM staging system of renal cell carci-
noma: a Swiss experience with 588 tumors. Cancer 89:604–614
18. Rabjerg M, Mikkelsen MN, Walter S, Marcussen N (2014)
Incidental renal neoplasms: is there a need for routine screening?
A Danish single-center epidemiological study. APMIS 122:708–
714
19. Zhou H, Zheng S, Truong LD, Ro JY, Ayala AG, Shen SS (2014)
Clear cell papillary renal cell carcinoma is the fourth most common
histologic type of renal cell carcinoma in 290 consecutive nephrec-
tomies for renal cell carcinoma. Hum Pathol 45:59–64
20. Dhakal HP, McKenney JK, Khor LY, Reynolds JP, Magi-Galluzzi
C, Przybycin CG (2016) Renal neoplasms with overlapping fea-
tures of clear cell renal cell carcinoma and clear cell papillary renal
cell carcinoma: a clinicopathologic study of 37 cases from a single
institution. Am J Surg Pathol 40:141–154
21. Tickoo SK, dePeralta-Venturina MN, Harik LR et al (2006)
Spectrum of epithelial neoplasms in end-stage renal disease: an
experience from 66 tumor-bearing kidneys with emphasis on his-
tologic patterns distinct from those in sporadic adult renal neopla-
sia. Am J Surg Pathol 30:141–153
22. Végső G, Toronyi E, Hajdu M et al (2011) Renal cell carcinoma of
the native kidney: a frequent tumor after kidney transplantationwith
favorable prognosis in case of early diagnosis. Transplant Proc 43:
1261–1264
23. Breda A, Luccarelli G, Rodriguez-Faba O et al (2015) Clinical and
pathological outcomes of renal cell carcinoma (RCC) in native kid-
neys of patients with end-stage renal disease: a long-term compar-
ative retrospective study with RCC diagnosed in the general popu-
lation. World J Urol 33:1–7
24. Song C, Hong SH, Chung JS, Byun SS, Kwak C, Jeong CW, Seo
SI, Jeon HG, Seo IY (2016) Renal cell carcinoma in end-stage
disease: multi-institutional comparative analysis of survival. Int J
Urol 23:465–471
25. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L et al (2005)
Prognostic value of histologic subtypes in renal cell carcinoma: a
multicenter experience. J Clin Oncol 23:2763–2771
26. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson
RH, Blute ML, Cheville JC (2010) Histological subtype is an inde-
pendent predictor of outcome for patients with renal cell carcinoma.
J Urol 183:1309–1315
27. Capitanio U, Cloutier V, Zini L et al (2009) A critical assessment of
the prognostic value of clear cell, papillary and chromophobe his-
tological subtypes in renal cell carcinoma: a population-based
study. BJUI 103:1496–1500
28. Volpe A, Novara G, Antonelli A et al (2012) Chromophobe renal
cell carcinoma (RCC): oncological outcomes and prognostic factors
in a large multicentre series. BJU Int 110:76–83
29. Frees S, Kamal MM, Knoechlein L et al (2016) Differences in
overall and cancer-specific survival of patients presenting with
chromophobe versus clear cell renal cell carcinoma: a propensity
s c o r e ma t c h ed an a l y s i s . U r o l o gy. do i : 1 0 . 1016 / j .
urology.2016.05.048
30. Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ,
Lyles RH, Moch H (2008) Chromophobe renal cell carcinoma:
histomorphologic characteristics and evaluation of conventional
pathologic prognostic parameters in 145 cases. Am J Surg Pathol
32:1822–1834
31. Diolombi ML, Cheng L, Argani P, Epstein JI (2015) Do clear cell
papillary renal cell carcinomas have malignant potential? Am J
Surg Pathol 39:1621–1634
32. Cornejo KM, Dong F, Zhou AG et al (2015) Papillary renal cell
carcinoma: correlation of tumor grade and histologic characteristics
with clinical outcome. Hum Pathol 46:1411–1417
33. Warrick JI, Tsodikov A, Kunju LP et al (2012) Papillary renal cell
carcinoma revisited: a comprehensive histomorphologic study with
outcome correlations. Hum Pathol 45:1139–1146
34. Pichler M, Hutterer GC, Chromecki TF, Pummer K, Mannweiler S,
Zigeuner R (2013) Presence and extent of histological tumour ne-
crosis is an adverse prognostic factor in papillary type 1 but not in
papillary type 2 renal cell carcinoma. Histopathology 62:219–228
35. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H
(2002) An outcome prediction model for patients with clear cell
renal cell carcinoma treated with radical nephrectomy based on
tumor stage, size, grade and necrosis: the SSIGN score. J Urol
168:2395–2400
36. Lam JS, Shvarts O, Said JW et al (2005) Clinicopathologic and
molecular correlations of necrosis in the primary tumor of patients
with renal cell carcinoma. Cancer 103:2517–2525
37. The Cancer Genom Atlas Network (2016) Comprehensive molec-
ular characterization of papillary renal-cell carcinoma. N Engl J
Med 374:135–145
38. Becker A, Hickmann D, Hansen J et al (2016) Critical analysis of a
simplified Fuhrman grading scheme for prediction of cancer specif-
ic mortality in patients with clear cell renal cell carcinoma–impact
on prognosis. Eur J Surg Oncol 42:419–425
39. Pierorazio PM, JohnsonMH, Patel HD et al (2016) Management of
Renal Masses and Localized Renal Cancer: systematic review and
meta-analysis. J Urol. doi:10.1016/j.juro.2016.04.081
40. Chamie K, Donin NM, Klöpfer P et al (2016) Adjuvant weekly
girentuximab following nephrectomy for high-risk renal cell carci-
noma: the ARISER randomized clinical trial. JAMA Oncol.
doi:10.1001/jamaoncol.2016.4419
698 L. Kuthi et al.
ORIGINAL ARTICLE
Renal Cell Carcinoma with Clear Cell Papillary Features: Perspectives
of a Differential Diagnosis
Áron Somorácz1 & Levente Kuthi2 & Tamás Micsik3 & Alex Jenei2 & Adrienn Hajdu2 & Brigitta Vrabély3 &
Erzsébet Rásó1 & Zoltán Sápi3 & Zoltán Bajory4 & Janina Kulka1 & Béla Iványi2
Received: 22 May 2019 /Accepted: 1 October 2019
# The Author(s) 2019
Abstract
Thirty-one cases of low-grade renal cell carcinoma (RCC) with clear cells and tubulopapillary/papillary architecture were
analyzed retrospectively with immunohistochemical and genetic markers to gain more experience with the differential diagnosis
of such cases. All samples coexpressed CK7 and CA9; the TFE3 or TFEB reactions were negative; the CD10 and the AMACR
stainings were negative in 27 cases and 30 cases, respectively. The FISH assays for papillary RCC, available in 27 cases, and
deletion of chromosome 3p, available in 29 cases, gave negative results. The results for 3p deletion, VHL gene mutation or VHL
gene promoter region hypermethylation testing, along with the diffuse CD10-positivity in 2 cases confirmed 21 cases as clear cell
papillary RCC (CCPRCC; CK7+, CA9+; no 3p loss, no VHL abnormality) and 10 cases as clear cell RCC (CCRCC; CK7+,
CA9+; no 3p loss, VHL abnormality mutation/hypermethylation present). In CCPRCCs, the representative growth pattern was
branching tubulo-acinar, commonly accompanied by cyst formation. The linear nuclear arrangement or cup-shaped staining of
CA9 did not necessarily indicate CCPRCC, and the absence of these did not exclude the diagnosis of CCPPRC. One tumor
infiltrated the renal sinus; the others exhibited pT1 stage; and metastatic outcome was not recorded. The CCRCC cases were in
pT1 stage; 6 exhibited cup-shaped staining of CA9, and 1 displayed lymph node metastasis at the time of surgery. Distant
metastatic disease was not observed. In summary, the VHL abnormalities distinguished the subset of CCRCC with diffuse CK7-
positivity and no 3p loss from cases of CCPRCC.
Keywords Clear cell carcinoma . Clear cell papillary carcinoma . Cytokeratin 7-positivity . Differential diagnosis . VHL gene
Introduction
Clear cell papillary renal cell carcinoma (CCPRCC) is an in-
frequent subset of RCC [1, 2]. Although CCPRCC shares
histopathogical features with clear cell RCC (CCRCC), pap-
illary RCC and Xp11.2 translocation RCC, its immunohisto-
chemical coexpression of cytokeratin 7 (CK7) and carbonic
anhydrase 9 (CA9), and negativity for CD10, alpha-methyl-
CoA racemase (AMACR), and TFE3 usually clarifies the di-
agnosis [3–7]. The renal angiomyoadenomatous tumor (RAT)
is now regarded as being in the spectrum of CCPRCC [8–10].
Genetically, CCPRCCs lack chromosome 3p deletion or VHL
gene mutation or VHL promoter hypermethylation, the hall-
marks of CCRCC, and have no loss of chromosome Yor gain
of chromosome 7 and 17, the hallmarks of papillary RCC
[2–4, 11–13].
In surgical pathology practice, the separation of CCPRCCs
from CCRCCs can pose certain difficulties. The distinction is
crucial, because CCPRCCs have a very limited potential for
metastasis (fatal outcome has been reported only in two pa-
tients out of 400 [14]), whereas in low-grade CCRCCs distant
metastases can occur several years after nephrectomy. To learn
more about the differential diagnosis of low-grade RCCs with
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CCPRCC features, a series of such tumors were subjected to a
retrospective immunohistochemical analysis, applying CK7,
CA9, CD10, AMACR, TFEB and TFE3 immunostainings,
and the immunophenotypes were correlated with the results
of genetic markers for CCRCC or papillary RCC.
Materials and Methods
Case Selection and Review Process
This study was conducted with the permission of the Medical
Research Council (17489-4/2017/EKU). The hematoxylin
and eosin-stained slides of 2326 consecutive RCC samples
were reexamined for clear cell papillary RCC-like tumors,
including low-grade nuclei, the presence of any degree of
tubulopapillary growth pattern of tumor cells with clear cyto-
plasm, linear arrangement of nuclei away from the basal mem-
brane, along with the presence of a leiomyomatous stroma.
Demographical and clinical data were collected from the da-
tabase management systems of Semmelweis University and
University of Szeged.
Tissue Microarray and Immunohistochemical
Reactions
Tissue microarray blocks were prepared for immunohisto-
chemistry with TMA Master (3DHISTECH) applying a
2 mm core diameter. One to four representative cores were
t h e n p u n c h e d o u t f r o m t h e d o n o r b l o c k s .
Immunohistochemical staining for CA9, CK7, CD10,
AMACR, TFEB and TFE3 were performed (see the
dilutions and sources in Supplementary Table 1). The epitope
retrieval was performed for each antibody according to the
manufacturer’s recommendations. The reactions were con-
ducted using Autostainer (Dako). Afterwards, slides were
evaluated microscopically by estimating the proportion (%)
of immunopositive cells. Staining in over 50% of the tumor
cells, in 10 to 50% of tumor cells, or in less than 10% of the
tumor cells, was interpreted as diffusely or focally positive or
negative, respectively.
Fluorescent in Situ Hybridization (FISH)
FISH assays were carried out to detect either the loss of chro-
mosome 3p and chromosome Yor gain of chromosome 7 and
17. Tissue sections were cut from the TMA blocks and
deparaffinized. The assays were done using a VHL/cen3 probe
(ZytoLight® SPEC VHL/CEN3 Dual Color Probe,
Zytovision,) and centromeric probes for chromosome 7, 17
and Y (Cytocell) according to the manufacturer’s instructions.
Slides were digitalized by using a Pannoramic Midi slide
scanner (3DHISTECH), and reactions were evaluated using
a Pannoramic Viewer (3DHISTECH) in the following way.
Fifty tumor cells from each case were examined and were
compared with the same number of cells of the peritumoral
tissue, which served as an internal control. The cutoff values
of chromosomal gain and/or loss were set at the mean ±3SD of
the corresponding control values, as done in previous studies
[5]. The analysis of 3p deletion was also performed based on a
published method [15].
VHL Gene Sequence Analysis and VHL Gene Promoter
Hypermethylation
A PCR-based amplification method was used for VHL gene
mutation analysis as earlier described [16]. The VHL exons
were amplified via specific primer pairs (Supplementary
Table 2). In the case of pathological mutation, the apparently
tumor-free renal tissue was analyzed as well. A GenomeLAB
DTCS - Quick Start Kit (Beckman Coulter) was used for
DNA sequencing. The latter was carried out according to the
manufacturer’s instructions using the GenomeLab GeXP
Genetic Analysis System (Beckman Coulter). The methyla-
tion status of VHL gene promoter region was determined
using the methylation-specific PCR method. The extracted
genomic DNA was modified using the EpiJET Bisulfite
Conversion Kit (ThermoFischer Scientific), and followed by
PCR-based amplification with methylation-specific primer
pairs (Supplementary Table 3). The methylation status (non-
methylated, methylated) was determined by gel electrophore-
sis of the PCR products, as reported previously [17].
Criteria for Diagnosing a Tumor as CCPRCC
The diagnosis of CCPRCC was made if the above-mentioned
morphology together with characteristic immunophenotype
(CK7- and CA9-positivity, negative CD10 or at most focal
CD10-positivity, negative TFE3 and TFEB stainings), along
with the lack of genetic alterations indicating CCRCC (3p
deletion, VHL mutation, VHL promoter hypermethylation),
and PRCC (7 and 17 trisomy, loss of Y) were detected.
Tumors with the same morphology, CK7 and CA9
coexpression, but with diffuse CD10-positivity or with altered
VHL status were classed as CCRCC.
Results
Using the inclusion criteria, we retrieved 31 samples. All tu-
mors coexpressed CK7 and CA9. The TFE3 and TFEB reac-
tions were uniformly negative; and the CD10 and the
AMACR reactions were negative in 27 and 30 cases, respec-
tively. The FISH assays for papillary RCC, available in 27
cases, and deletion of chromosome 3p, available in 29 cases,
yielded negative results. The histomorphology, the results for
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VHL mutation and VHL methylation testing, and the
immunophenotype confirmed 21 cases as CCPRCC and 10
cases as CCRCC. The principal characteristics of the two sub-
sets are summarized in Tables 1 and 2.
Features of CCPRCCs
Here, 21 tumors were examined, and the specimens were ob-
tained from 12 females and 9 males. The mean age was 60
years (with range 28 to 84 years). Partial nephrectomy was
performed in 4 patients and radical nephrectomy in 17 pa-
tients; and one tumor developed in a transplanted kidney.
Twenty cases were incidental findings of imaging performed
for non-urological symptoms.
Gross Findings
All the tumors were solitary, and the mean size was 23 mm
(with range 6 to 65 mm). Cystic change was present in 12
samples; and multilocular cystic mass existed in cases 7 and
15. The tumorous parenchyma was grey-white to yellow-
brown, occasionally with small hemorrhagic foci.
Microscopic Findings
Each tumor was circumscribed, and at least one thin fibrous,
or fibromuscular capsule was present, except in one case. The
capsule was thick (400-800 μm) and contained smooth mus-
cle in 13 tumors. A minimal infiltration of renal sinus fat was
observed in Case 3 (Fig. 1a, b). Vascular invasion was not
detected in any of the cases examined. The dominant growth
pattern was tubulo-acinar (15 tumors), with cyst formation in a
continuum from microscopic to macroscopic cystic spaces in
12 samples. Also, a papillary architecture was observed in 14
tumors and was detected mainly focally, except in one case
where it was predominantly seen. Solid areas with compact
cell nests and trabeculae were seen in 11 samples, and it was
mostly made up of a small proportion of the tumorous paren-
chyma. Foamy macrophages, psammoma bodies and necrosis
were absent. Although the clear cell phenotype was a distinc-
tive feature, the tumor cells displayed various cytological
characteristics. Most of them were cuboidal or columnar, but
flattened forms in cysts, as well as elongated cells arranged
focally in a fascicular pattern in solid areas were also encoun-
tered. Some tumor cells – especially in solid areas – had eo-
sinophilic cytoplasm. Prominent nucleoli were not present.
The linear arrangement of nuclei together with its orientation
away from the basement membrane was observed in 16 tu-
mors (from a minimal to an extensive presence). Mitotic fig-
ures were occasionally seen. Stromal smooth muscle was
found in 18 cases including two samples with abundant myo-
matous stroma (cases 1 and 7).
Immunohistochemical and Molecular Profile
All tumors exhibited a strong and diffuse CK7 expression.
Immunoreaction for CA9 resulted in diffuse staining in 17
tumor samples, and focal staining in 4 tumor samples. The
Bcup-shaped^ pattern was detected in 17 cases, visible mainly
in the tubular and cystic areas. Focal CD10-positivity was
found in 2 samples. Weak granular, diffuse AMACR-
positivity was noted in Case 14.
The mutation status of the VHL gene was investigated in 11
samples, and in Case 12, single nucleotide polymorphism (SNP)
in untranslated region (UTR) was found. The VHL gene promot-
er hypermethylation statuswas analyzed in 16 samples; and none
of these harbored promoter region hypermethylation.
Follow-up
The median time was 52.5 months (with range 1 to 184
months). Three patients did not have a follow-up, and two
patients died in non-cancer-related causes. No evidence of
tumor progression and recurrence was documented in the data
of the 18 surviving patients.
Features of CCRCCs Mimicking CCPRCC
In this group, we analyzed 10 cases, and the mean age was 51
years (with range 37 to 69 years) with 5 female and 5 male
patients. Half of the cases were treated via partial nephrectomy.
Tumor-related symptomswere registered in two patients. In Case
23, a CCRCC (CA9 and CD10: diffusely positive; CK7 nega-
tive) was resected from the contralateral kidney twomonths after
the first surgery. And in Case 24, a metastatic perihilar lymph
nodewas removed together with the tumorous kidney (Fig. 1c-f).
Gross Findings
The mean size of the tumors was 29 mm (with range 15 to 50
mm). Cystic change was noticed almost in all cases (9/10).
The cut surface was indistinguishable from those seen in
CCPRCC.
Microscopic Findings
A capsule containing smooth muscle was present in 6 cases.
The predominant growth pattern was tubulo-acinar (5/10),
followed by cystic (2/10), papillary (1/10) and solid (1/10).
In Case 29, the distribution of tubulo-acinar, papillary and
cystic pattern was the same. The tumors were composed of
clear cytoplasm cells with focal eosinophilic granulations.
Also, an apical linear nuclear arrangement was noted in 6
cases, and 2 cases contained a smooth muscle rich stroma.
The infiltration of the renal vein, renal sinus and perinephric
fat tissue was not observed.
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Immunohistochemical and Molecular Profile
There was a coexpression of CK7 in a diffuse fashion
and CA9 in a diffuse (8 cases) or focal fashion (2
cases). The cup-shaped distribution of CA9 was present
in 6 cases. Diffuse CD10-positivity was observed in
cases 23 and 24.
The VHL gene mutation status was analyzed in 9 sam-
ples, and in cases 22, 23 and 31 a pathogenic mutation
was identified that was not present in the tumor-free
renal parenchyma (Fig. 2). The sequencing revealed an
SNP without any clinical significance in Case 24. The
remaining 5 tumors analyzed harbored no genetic
change. Also, the VHL gene promoter hypermethylation
was tested in 8 cases, and 7 of them possessed promoter
region hypermethylation.
Follow-up
All the cases had follow-up data with a median of 31.6months
(with range 3 to 100 months). None of them experienced any
recurrence and cancer-related death.
Table 1 Clinicopathological features of the cases examined
Patient Sex Age (y) ESRD Tumor-related
symptoms
Size (mm) AJCC Stage ISUP Grade Follow-up
period
(months)*
Progression§ Comment
Clear cell papillary RCC
1 M 68 No No 21 T1aNxMx 1 31 No
2 M 57 No No 20 T1aNxMx 2 35 No
3 M 64 No No 30 T3aNxMx 2 NA ND Sinus fat tissue infiltration
4 F 68 No No 30 T1aNxMx 1 12 No
5 M 84 ESRD No 10 T1aNxMx 1 1 No
6 F 63 No No 8 T1aNxMx 2 46 No Ipsilateral oncocytoma
7 F 81 No No 25 T1aNxMx 1 113 No
8 F 78 No No 20 T1aNxMx 1 184 No
9 M 56 ACKD No 10 T1aNxMx 1 85 No
10 M 66 No No 11 T1aNxMx 1 3 No
11 F 49 No No 38 T1aNxMx 1 10 No
12 M 75 No No 65 T1bNxMx 2 80 No
13 F 52 No No 25 T1aNxMx 2 158 No
14 M 32 No No 8 T1aNxMx 1 101 No
15 F 57 No No 6 T1aNxMx 1 NA ND
16 F 30 ESRD No 8 T1aNxMx 1 86 No
17 F 60 No Abdominal pain 22 T1aNxMx 1 3 No
18 M 76 No No 10 T1aN0Mx 1 62 No Ipsilateral angiomyolipoma
and papillary adenomas
19 F 69 No No 13 T1aNxMx 1 8 No
20 F 28 ESRD No 20 T1aNxMx 2 59 No Tumor in a graft kidney
21 F 56 No No 30 T1aNxMx 1 NA ND
Clear cell RCC
22 F 41 No No 20 T1aNxMx 1 26 No
23 F 44 No No 50 T1bN1Mx 1 36 No Lymph node metastasis
24 M 37 No Hematuria 37 T1aNxMx 1 67 No Contralateral clear cell RCC
two months later
25 M 47 ACKD No 19 T1aNxMx 1 12 No
26 F 53 No No 30 T1aNxMx 1 19 No
27 F 69 No No 24 T1aNxMx 2 37 No
28 M 69 No Lumbar pain 15 T1aNxMx 1 100 No Ipsilateral papillary adenoma
29 M 40 No No 30 T1aNxMx 1 10 No
30 F 51 No No 40 T1aNxMx 1 3 No
31 M 61 No No 25 T1aNxMx 2 6 No
*Follow-up, determined from the surgery to the last follow-up; §Progression, assessed by radiological and/or autopsy data
M male; F female; ESRD end-stage renal disease; ACKD acquired cystic kidney disease; NA not available; ND no data
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Discussion
The WHO classification of RCCs defines the subsets via a
synthesis of histopathological, immunohistochemical, and ge-
netic data [1]. In the current study, we focused on the discrim-
ination of CCPRCC from other tumor types by applying the
well-known immunohistochemical markers supplemented
with a molecular analysis that seeks to find chromosomal
abberations and VHL abnormalities (including mutations as
well as methylation analysis). We made a formal diagnosis
of CCPRCC when both the immunohistochemical and the
genetic tests were in complete accordance with the histology.
All the RCC subtypes with clear cell phenotype (i.e. TFE3
or TFEB translocation RCCs, TCEB1-mutated RCC [18],
Table 2 Morphological, immunohistochemical, and molecular characteristics of the cases examined.
Patient Architecture of tumor volume (%) Immune profile (%) Molecular characteristics
Tubular Papillary Cystic Solid LiN CK7 CA9 CA9 cup-shaped CD10 AMACR +7 +17 -
Y
-
3p
VHL mut VHL met
Clear cell papillary RCC
1 90 - - 10 No Diff Diff Yes Neg Neg - - - - wt ua
2 88 2 - 10 Yes Diff Diff Yes Foc Neg - - - - wt -
3 95 - - 5 Yes Diff Diff Yes Neg Neg nd nd nd nd nd nd
4 59 1 20 20 Yes Diff Diff Yes Neg Neg - - - wt -
5 100 - - - Yes Diff Diff Yes Neg Neg - nd - - nd nd
6 95 5 - - Yes Diff Diff Yes Foc Neg - - - wt -
7 44 5 50 1 No Diff Diff Yes Neg Neg - - - wt -
8 50 50 - - Yes Diff Diff Yes Neg Neg - - - ua -
9 80 10 - 10 No Diff Diff Yes Neg Neg - - - - wt -
10 95 5 - - Yes Diff Diff Yes Neg Neg - - - - wt -
11 50 40 10 - Yes Diff Diff Yes Neg Neg - - - wt -
12 50 - 50 - Yes Diff Diff Yes Neg Neg - - - - 5’UTR SNP# -
13 - 80 20 - No Diff Diff Yes Neg Neg - - - ua -
14 80 10 10 - Yes Diff Diff Yes Neg Poz§ - - - - wt -
15 - 20 80 - Yes Diff Diff No Neg Neg - - - ua nd
16 95 - - 5 Yes Diff Diff No Neg Neg - - ua nd
17 50 20 30 - No Diff Diff No Neg Neg - - - wt -
18 90 - 5 5 Yes Diff Foc Yes Neg Neg nd nd nd nd nd -
19 45 1 50 4 Yes Diff Foc Yes Neg Neg - - - nd -
20 89 - 1 10 Yes Diff Foc Yes Neg Neg - - - ua -
21 85 1 5 10 Yes Diff Foc No Neg Neg - - - ua -
Clear cell RCC
22 50 5 35 10 Yes Diff Diff Yes Neg Neg - - - muta +
23 50 20 30 - Yes Diff Diff Yes Diff Neg nd nd - mutb nd
24 10 50 20 20 No Diff Diff No Diff Neg - - - - 5’UTR SNP¶ -
25 80 10 10 - No Diff Diff Yes Neg Neg - - - - wt +
26 95 1 - 4 Yes Diff Diff Yes Neg Neg - - - wt +
27 20 10 70 - Yes Diff Diff Yes Neg Neg - - - wt +
28 40 - 60 - Yes Diff Diff Yes Neg Neg - - - - ua +
29 20 40 40 - Yes Diff Diff No Neg Neg - - - - wt +
30 30 - 20 50 No Diff Foc No Neg Neg - - - wt +
31 90 - - 10 Yes Diff Foc No Neg Neg - - - - mutc nd
LiN linear nuclear arrangement from basement membrane;+7 and +17 trisomy of chromosome 7 and 17, respectively; -Y deletion of chromosomeY; -3p
deletion of chromosome 3p; VHL mut, von Hippel-Lindau gene mutation status; VHL met, von Hippel-Lindau gene methylation status; nd not
determined; wt wild type; ua unsuccessful analysis; 5’UTR SNP single nucleotide polymorphism in 5’ untranslated region; diff diffuse; foc focal; neg
negative (less than or equal to 10%)
§ weak granular positivity; # exon 3 could not be amplified; ¶ exon1b could not be amplified; a c.221T>A/p.V74N; b c.625C>T/p.G209*; c c.354_
361delCTTCAGAGinsT
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RCC with 8p monosomy [19], RCC with prominent smooth
muscle stroma (RCCSMS) [20–25] and RCC associated with
von Hippel-Lindau syndrome) can exhibit a CCPRCC-like
histomorphology [26, 27], but CCRCC cases pose the biggest
difficulty because this tumor type is the most common and it
also has some morphological similarities. CCRCCs are
viewed as tumors that are CA9+ and CD10+, and display no
more than a focal CK7 positivity. In contrast, the
immunophenotype of CCPRCCs is CK7+, CA9+, and
CD10-. Perhaps diffuse and strong CK7 positivity is consid-
ered the most important and an obligatory diagnostic criterion
for CCPRCC. Nevertheless, the lack of a widespread CD10
reaction is also required.
We performed our case selection based on histological
features suggestive of CCPRCC, and all the tumors
displayed diffuse CK7 staining. In two of them, however,
Fig. 1 a-b Case 3 with sinus fat invasion The tumor showed a
branching tubular pattern and an immunophenotype characteristic for
CCPRCC (basolateral CA9 reaction in the insert) (a). Superficial
infiltration of sinus fat was seen (b). Figure 1 c-f Case 23 with lymph
node metastasis The tumor displayed the morphological features of
CCPRCC, partly with papillary architecture (c). The lymph node
metastasis was mainly cystic; with some papillary infoldings (insert in
figure d) (d). The tumor exhibited a diffuse CK7 positivity (e), but
extensive CD10 staining was also observed (f). The latter, together with
the VHL genemutation detected in this tumor were not consistent with the
diagnosis of CCPRCC
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CD10 positivity was also diffuse, which supported our
diagnosis of CCRCC. In another subset of our cases,
the morphology and immunophenotype wholly favoured
the diagnosis of CCPRCC; however, either VHL muta-
tion (3 cases) or VHL promoter hypermethylation (7
cases) was present. We accepted the view of Hes et al.
who recommended not classifying cases with any VHL
gene abnormality as CCPRCC [28]. Based on their ap-
proach, our tumors with altered VHL status were classi-
fied as CCRCC.
After performing an immunohistochemical and molecular
analysis, our selected cases with histology of CCPRCCs were
subdivided into two groups. These are CCPRCCs (21 cases),
and CCRCCs with diffuse CK7 positivity (10 cases).
Features of CCPRCC Cases
The characteristic pattern of these tumors was branching
tubulo-acinar that was commonly accompanied by cyst for-
mation. Papillary areas, however, were detected as a minor
Fig. 2 Case 22 exhibiting morphology and immunophenotype
completely consistent with CCPRCC, but containing a VHL gene
mutation. The tumor had a thick fibromyomatous capsule and it was
composed of both solid and cystic areas (a). Branching tubular
architectural pattern was the most characteristic (b). The tumor cells
were diffusely positive for CK7 (c); and negative for CD10 (d). CA9
immunoreaction also resulted in a diffuse staining with a basolateral
pattern (e). VHL gene mutation was detected by direct sequencing (f)
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component except in three cases. As similar findings on the
extent of papillarity were obtained by Aydin et al. [5] and by
Williamson et al. [29], we conclude that CCPRCC with pre-
dominant papillarity probably occurs quite rarely. Therefore,
the WHO designation of this entity seems inaccurate, and the
appellation Btubulopapillary^ would perhaps be more apt, as
was suggested by Aydin et al [5].
Linear nuclear arrangement away from the basement mem-
brane is regarded as characteristic for CCPRCC [30].
Actually, 16/21 of CCPRCCs and 7/10 CCRCCs with diffuse
CK7-positivity harbored this phenomenon (from a minimal to
extensive presence). Dhakal et al. examined 37 tumors with a
morphologic overlap between CCPRCC and CCRCC fea-
tures, and linear nuclear arrangement was not the exclusive
feature of cases classified as CCPRCC [31]. In another series
of CCPRCC, Williamson at al. noticed linear nuclear arrange-
ment only in 24/55 cases [32]. These findings suggest that
linear nuclear arrangement is an overemphasized phenome-
non, since its absence does not exclude the possible diagnosis
of CCPRCC, and its presence does not necessarily support the
diagnosis of CCPRCC.
The cup-shaped expression of CA9 was not uniformly
present in our series. A diffuse cup-shaped expression was
observed in 17/21 samples, while a dominant box-shaped
staining with a focal cup-shaped expression was noted in 4/
21 samples. Upon reviewing the literature, a cup-shaped ex-
pression involving 50% of tumor cells was reported by Rohan
et al. in 3 out of their 9 cases [6]; and Dhakal et al. noted a cup-
like expression of CA9 in 74% of their cases [31]; and Aydin
et al. did not mention this feature at all in their 36 cases [5].
Since in our experience the cup-shaped staining pattern cannot
be discerned unambiguously in solid areas, the absence of
cup-shaped expression should be interpreted with caution
when making a concrete diagnosis of CCPRCC for a specific
case. A diffuse and weak granular AMACR-positivity was
seen in one case. We reviewed the immunoprofile of the pub-
lished CCPRCC cases and, albeit rarely, AMACR-positivity
was reported [5, 6, 11, 29, 32–34]; hence if it is present, it does
not necessarily contradict the diagnosis of CCPRCC. Focal
CD10-positivity was encountered in two, otherwise complete-
ly typical CCPRCC, and VHL gene abnormalities were not
present in these samples. The focal extent of CD10 expression
may indicate the possibility of RAT, because a lack of a cystic
component viewed microscopically, and the triple
coexpression of CK7, CA9 and a certain degree of CD10 were
noted in a series of RCC cases classified as RAT [35].
Our CCPRCC group comprised 19 pT1a, 1 pT1b and 1
pT3a cases, respectively. To our knowledge, ours is the first
reported case with infiltration outside of the kidney parenchy-
ma. Also, in Case 20 the tumor developed in a transplanted
kidney. In a recently published review, Dhakal at al. [36] sum-
marized the findings of 24 articles that reported tumors in
transplanted kidneys, but among the 48 tumors described,
not one was CCPRCC. Coexisting benign tumors and
CCPRCC were observed in two cases. Actually, in Case 6
the oncocytoma had been detected clinically, and during
the grossing CCPRCC was discovered. All of our CCPRCC
cases had an excellent clinical outcome, reinforcing the
view that the carcinoma designation might be exaggerated
[14, 37, 38].
Features of CCRCCs with Diffuse CK7-Positivity
A series of CCRCC with diffuse CK7-posivity was published a
decade ago by Mai et al [39]. Similar to our experiences, these
samples were small-sized, and a non-metastatic course was re-
corded over a mean of a 3-year follow-up; and diffuse CK7-
positivity was viewed as the indicator of indolent behaviour [40].
Our results provide further clinicopathologic data on this
rare subset of CCRCC. Accordingly, neither 3p deletion, nor
other chromosomal anomalies were present. The VHL gene
sequence analysis revealed pathologic mutations in cases 22,
23 and 31. Since VHL mutations were not identified in the
non-tumorous renal tissue, the possibility of VHL-disease-
associated CCRCC was excluded.
In seven samples, the histological and immunphenotypic
data favoured the diagnosis of CCPRCC; however, the pres-
ence of the VHL gene promoter hypermethylation abnormality
leads us to place these samples into the CCRCC group. In the
study of Herman et al. on silecing of the VHL gene by DNA
methylation, the hypermethylation of a CpG island in the 5’
region was noted in 5 samples out of 26 CCRCCs [16]. Four
of these had lost one copy of VHL, while one retained two
heavily methylated alleles. The latter observation indicated
Table 3 Overlapping and discriminating features of CCRCCs and
CCPRCCs. As we accepted the view of Hes et al. [18] that VHL gene
alteration is not compatible with the diagnosis of CCPRCC, altered VHL
status was found as the most reliable discriminating feature between
CCRCCs and CCPRCCs in our cohort
Tubulopapillary
architecture
Subnuclear
vacuolization
Stromal
SM
Diffuse
CK7+
Diffuse
CD10+
CA9 cup-
shaped
-
3p
VHL
mut
VHL
met
CCCRCC +/- +/- +/- +/- +/- +/- +/- +/- +/-
CCCPRCC + +/- +/- + - +/- - - -
SM smooth muscle; mut mutation; met hypermethylaiton
Á. Somorácz et al.
that hypermethylation may inactivate the VHL gene even
when both wild-type alleles are retained [16]. In our analysis,
hypermethylation was noted in seven cases; moreover
coexisting VHL gene mutation and methylation was seen in
Case 22. After a search for methylation data, only 2 tumors
analyzed were found in the literature out of 400 or so
CCPRCCs [5, 14]. Methylation analyses performed by others
in the futuremay validate our assumption that a VHL promoter
hypermethylation is definitely not compatible with the diag-
nosis of CCPRCC. In Case 24 (and in Case 12 in the
CCPRCC group) an SNP was observed in the 5’ UTR region,
a finding treated as insignificant, because the nucleotide
change did not induce any amino acid change as well.
Interestingly, in 8 cases the histological and immunphenotypic
data were entirely consistent with the histopathological diag-
nosis of CCPRCC, but the presence of VHL abnormalities led
us to place these samples into the group of low-grade CCRCC
with CK7 immunoreactivity and no 3p loss. Every case was in
the pT1 stage, and there was no progression or recurrence.
In summary, in our study the immunophenotype and the
genetic profile of 31 RCCs composed of clear cells, low-grade
nuclei and a tubulopapillary architecture were investigated
retrospectively. Twenty-one cases were classified as
CCPRCC (CK7+, CA9+; -3p absent, VHL abnormality not
present) and 10 as CCRCC with diffuse CK7-positivity
(CK7+, CA9+; -3p absent, VHL abnormality present). Based
on our findings, the following conclusions can be drawn. First,
CCPRCCs rarely exhibit a predominant papillary architecture,
hence their name is misleading. Second, a linear nuclear ar-
rangement away from the basement membrane and cup-like
CA9 positivity are not obligatory features. Third, the evidence
for their malignant potential is still subject of debate. Fourth,
RCCs with CCPRCC morphology, diffuse CK7 positivtiy,
and with an altered VHL status (mutation, or promoter hyper-
methylation) do exist; and these tumors can be interpreted as
CCRCCwith diffuse CK7 positivity, and they can be definite-
ly differentiated from CCPRCCs only by carrying out molec-
ular tests for the VHL status. And last but, not least the bio-
logical behavior of both CCPRCCs and CCRCCs with diffuse
CK7 positivity seems to be indolent with a favorable clinical
outcome. Overlapping and discriminating features of
CCPRCCs and CCRCCs are summarized in Table 3.
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Abstract
Xp11.2 translocation carcinoma is a distinct subtype of renal cell carcinoma characterized by translocations involving the TFE3
gene. Our study included the morphological, immunohistochemical and clinicopathological examination of 28 Xp11.2 RCCs.
The immunophenotype has been assessed by using CA9, CK7, CD10, AMACR, MelanA, HMB45, Cathepsin K and TFE3
immunostainings. The diagnosis was confirmed by TFE3 break-apart FISH in 25 cases. The ages of 13 male and 15 female
patients, without underlying renal disease or having undergone chemotherapy ranged from 8 to 72. The mean size of the tumors
was 78.5 mm. Forty-three percent of patients were diagnosed in the pT3/pT4 stage with distant metastasis in 6 cases. Histological
appearance was branching-papillary composed of clear cells with voluminous cytoplasm in 13 and variable in 15 cases, including
one tumor with anaplastic carcinoma and another with rhabdoid morphology. Three tumors were labeled with CA9, while CK7
was negative in all cases. Diffuse CD10 reaction was observed in 17 tumors and diffuse AMACR positivity was described in 14
tumors. The expression of melanocytic markers and Cathepsin K were seen only in 7 and 6 cases, respectively. TFE3 immuno-
histochemistry displayed a positive reaction in 26/28 samples. TFE3 rearrangement was detected in all the analyzed cases (25/
25), including one with the loss of the entire labeled break-point region. The follow-up time ranged from 2 to 300 months, with 7
cancer-related deaths. In summary, Xp11.2 carcinoma is an uncommon form of renal cell carcinoma with a variable
histomorphology and rather aggressive clinical course.
Keywords Translocation renal cell carcinoma . Xp11.2 . Immunohistochemistry .TFE3 gene . Fluorescence in situ hybridization
(FISH)
Introduction
In the current classification scheme there are 13 distinct types
of renal cell carcinoma (RCC), and one of them is the Xp11.2
translocation RCC. It is a rare subtype and is characterized by
different translocations involving the transcription factor 3
gene (TFE3), that leads to a new fusion gene encoding an
aberrant transcription factor [1]. Five common partner genes
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were identified including ASPL-TFE3: t(X;17)(p11.2;q25),
PSF - TFE3 : t ( X ; 1 ) ( p 11 . 2 ; p 3 4 ) , PRCC - TFE3 :
t(X;1)(p11.2;q21), CLTC-TFE3: t(X;17)(p11.2;q23) and
NonO-TFE3: t(X)(p11.2q12) so far in the literature [2–5].
Although Xp11.2 RCC was described as a malignancy among
children and adolescents, cases from adults and elders were
also reported [6, 7]. The prognosis is controversial, since
Xp11.2 RCC has an indolent behavior in children, however,
new reports on an aggressive clinical course in adults has been
reported as well [6, 8]. Tumor cells usually have blank cyto-
plasm that mimics clear cell RCC, although the growth pattern
is frequently papillary, with psammoma bodies often present
[9]. Xp11.2 RCC displays negativity with carbonic anhydrase
9 (CA9) and CK7 [10, 11], while CD10 is often positive and
the expression of the melanocytic markers (MelanA and
HMB45) are frequent, although they are not expressed in oth-
er subsets of RCC [6]. Cathepsin K is a novel marker for
Xp11.2 RCC and its positivity indicates the presence of fusion
gene PRCC-TFE3 [12]. The result of translocations involving
the TFE3 gene is the overexpression of the TFE3 protein that
can be detected by immunohistochemistry [13]. Although nu-
clear positivity of the TFE3 protein is a useful diagnostic
marker, false negativity and positivity may occur, therefore
the identification of the TFE3 gene rearrangement by fluores-
cent in situ hybridization (FISH) is needed to confirm the
diagnosis [13]. The prognosis of Xp11.2 RCC is still unclear
because of the low appearance of series including a great
number of patients and the short follow-up period [6]. The
three main aims of this retrospective study were: (1) to deter-
mine the frequency of Xp11.2 RCC in a large set of surgically
treated renal tumors; (2) to provide detailed survival data; and
(3) to analyze the morphological features with immunohisto-
chemical and genetic profile to help pathologists establish an
accurate histological diagnosis.
Material and Methods
Case Selection
A retrospective study was performed that included morpho-
logical, immunohistochemical and molecular pathological
analysis. The cases were collected from the Department of
Pathology, University of Szeged (1512 own and 64 consulta-
tion cases), the 2nd Department of Pathology, Semmelweis
University (818 cases), and the 1st Department of Pathology
and Experimental Cancer Research, Semmelweis University
(404 cases). The diagnostic criteria for Xp11.2 RCC were the
typical morphological pattern or moderate-to-strong nuclear
positivity with TFE3 immunohistochemistry or a positive
TFE3 break-apart FISH analysis. A total of 28 cases of
Xp11.2 RCC were diagnosed from 2804 tumors in the three
cen t e r s . A l l t umor s we r e s e l e c t ed f o r fu r t he r
immunohistochemical analysis. The main clinical data includ-
ed age, sex and symptoms at the time of the diagnosis. Follow-
up data were collected from the general practitioners, patient
records as well as the patient database of the University of
Szeged and Semmelweis University. Tumor size and AJCC
TNM stage were obtained from the original histopathological
report, however, the TNM stage was amended according to
the eighth edition of AJCC TNM staging. All the
hematoxylin-eosin stained slides were reviewed by three pa-
thologists (LK, ÁS, TM) to reevaluate the grade according to
the ISUP criteria, the histological pattern (generally papillary
or solid pattern) and to estimate the percentage of the cellular
morphology (predominantly clear or eosinophilic cells). The
presence of foamy cells, intracellular pigment, cholesterol
clefts, necrosis and psammoma bodies were also recorded,
though the extent of necrosis was not scored.
Immunohistochemistry (IHC) and Tissue Microarray
(TMA)
The IHC reactions were carried out on TMA. The recipient
TMA block was constructed by using a TMA Master
(3DHISTECH Ltd., Budapest, Hungary). Stated briefly, from
the most representative paraffin blocks of the tumors, two
cylindrical cores of 2 mm in diameter were punched out man-
ually. For IHC labeling a panel of antibodies listed in Table 1
was used. Only membrane labeling for CA9, and nuclear la-
beling for TFE3 was treated as positive. The scoring was
performed in a semiquantitative manner and the cases were
classified into three categories, namely negative (no staining
or less than 5% of positive cells), focally positive (5–75% of
positive cells) and diffusely positive (76–100% of positive
cells).
TFE3 Break-Apart FISH Analysis
Fluorescent in situ hybridization assays were carried out
to detect TFE3 gene rearrangement. Four μm thick sec-
tions were cut from the TMA blocks. The sections were
deparaffinized and the reaction was carried out by using
ZytoLight® SPEC TFE3 dual color break-apart FISH
probe (ZytoVision GMBH, Bremerhaven, Germany) ac-
cording to the manufacturer’s instructions. The slides
were counterstained with 4′, 6-diamidino-2-phenylindole
(DAPI, Abbott Laboratories, Abbott Park, IL, USA) and
scanned with a Pannoramic Midi s l ide scanner
(3DHISTECH Ltd., Budapest, Hungary). The evaluation
wa s p e r f o rmed by u s i ng Panno r am i c Vi ewe r
(3DHISTECH Ltd., Budapest, Hungary). One hundred
nuclei were counted and FISH reaction was considered
positive when over 10% of the neoplastic nuclei displayed
TFE3 rearrangement.
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Results
Twenty-eight tumors proved to be Xp11.2 RCC among 2804
nephrectomies reviewed by the three pathology departments
(0.99%). The diagnosis was suspected mainly because of the
histological appearance. The diagnosis was later confirmed by
IHC in each case and by FISH analysis except for patient #11,
#12 and #24.
Clinical Data and Follow-Up
The clinicopathological findings are summarized in Table 2.
Thirteen male and fifteen female patients were included in our
cohort. The median age was 60 years (with range from 8 to
72). Three tumors occurred in children andWilms’ tumor was
suspected in all cases. The tumor produced symptoms in 9
patients; in patient #22 a severe pain was provoked by distant
bone metastasis. The tumor was an incidental finding in 7
patients. There were no underlying renal disorders in any pa-
tients in the affected kidney, but in patient #12 contralateral
kidney agenesis was present. None of the examined patients
had received chemotherapy or had had previous malignant
tumors, although pharyngeal carcinoma developed in patient
#2 after the nephrectomy.
Radical nephrectomy was performed in each case except
three patients, who were treated with nephron-sparing ne-
phrectomy (tumor resection) because of the relatively small
tumors (patient #7 and #8) or the absence of the contralateral
kidney (patient #12).
Follow-up information was accessible in 21/28 patients
and the mean follow-up time was 51 months (with range from
2 to 321 months). Regional lymph node or distant metastasis
developed in 13 patients (9 had been discovered before sur-
gery; 6 distant and 3 regional lymph node metastases). Seven
patients died from cancer-related causes and one patient died
from a non-cancer-related cause. In patient #15 a regional
lymph node metastasis developed after 12 months so she
was treated with retroperitoneal lymphadenectomy and at the
last follow-up there were no signs of the disease. However,
60 months after the nephrectomy, patient #14 had multiple
pulmonary, hepatic and bone metastases. He received tyrosine
kinase and mTOR inhibitors until treatment failure. In patient
#27multifocal vertebral metastases developed. She is current-
ly receiving tyrosine kinase therapy and stable. The remaining
11 patients were alive with no evidence of disease.
Morphological Aspects
All the examined tumors were unilateral and unifocal. The
largest diameter of the tumors ranged from 15 mm to
160 mm and the average was 78.5 mm. In two cases the actual
size of the tumor was unknown. Macroscopically the cut sur-
face was usually solid and cystic with sulfur yellow color, as
seen in clear cell RCC. Foci of necrosis or hemorrhage were
occasionally noted as well. The invasion of the renal vein,
sinus and adipose capsule was observed in 7, 8, 6 cases re-
spectively. The predominant architectural appearance was sol-
id pattern (13/28), followed by papillary pattern (11/28), while
both solid and papillary patterns were seen in a small propor-
tion of cases (4/28). Tumors were composed mostly of clear
cells in 19 cases, mostly of eosinophilic cells in 7 cases and
mixed clear cell and eosinophilic morphology was seen in 2
cases. Twenty-two cases had typical architecture with volumi-
nous clear cytoplasm, nested or papillary growth. The remain-
ing 6 cases had diverse architecture, mostly mimicking clear
cell RCC, except for patient #5, whose tumor resembled
rhabdoid morphology and patient #6, whose tumor had ana-
plastic carcinoma appearance. The presence of foamy cells,
intracytoplasmic pigment, cholesterol clefts, psammoma bod-
ies and necrosis were observed in 7, 4, 1, 11 and 17 cases
respectively. Most of the tumors had high-grade nuclear fea-
tures (19/28). Detailed summary of the microscopic findings
can be found in Table 3. Figures 1 and 2 include representative
images of the morphological features.
IHC Findings
Results of immunohistochemistry are summarized in Table 4
and representative pictures are presented on Fig. 3. Three
cases displayed positivity with CA9, although two of these
were necrotic tumors. All the examined cases were negative
with CK7, while CD10 was strongly positive in 17 cases.
Table 1 List of the antibodies
used in the study Antibody Clonality/Source/Clone Concentration
CA9 rabbit polyclonal, Novus Biologicals 1/2000
CK7 mouse monoclonal, Cell Marque, OV-TL 12/30 1/100
CD10 mouse monoclonal, Biocare Medical, CM129 1/50
AMACR rabbit polyclonal, Abcam 1/100
MelanA mouse monoclonal, Labvision, A103 1/200
HMB45 mouse monoclonal, Cell Marque, hmb-45 1/200
TFE3 rabbit monoclonal, Cell Marque, mrq-37 1/100
Cathepsin K mouse monoclonal, Abcam, 3f9 1/100
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AMACR was negative in 14 tumors and a diffuse-to-focal
positivity was seen in the remaining 14 cases. The diagnostic
TFE3 reaction strongly labeled the nuclei in 26/28 cases, how-
ever, Cathepsin K displayed positivity only in 6 tumors.
MelanA was positive in four cases and HMB45 showed a
weak-to-diffuse positivity in three patients.
FISH Findings
FISH reaction was performed in 25 cases, because in pa-
tient #11, #12 and #24, the quality of tumor tissue was not
appropriate for proper molecular analysis. For the above-
mentioned three cases, FISH was repeated using the
original paraffin blocks, although the test remained unsuc-
cessful. In 21 tumors typical split signals were seen
(Fig. 4 A), while in patient #9 and #10 truncated signal
pattern was mostly observed (Fig. 4 B). In patient #14,
signals were separated, even though they were unusually
close to each other (Fig. 4 C). In patient #23 (a female) an
entire break-point region was completely absent (Fig. 4
D). Hence in this case only one signal pair was detected
in the nuclei of the tumor cells, while in the surrounding
renal parenchyma two unaffected signal pairs were pres-
ent. The immunophenotype and histomorphology led us
to classify the case as Xp11.2 RCC. No other abnormal-
ities were seen by using FISH in any cases.
Table 2 Clinicopathological features of the patients
Age (y) Sex Symptoms† Side Size (mm) pT Stage Node Status§ Metastasis or recurrence* Follow-up (mo) Status
1 52 M – L 70 4 – – – LTF
2 69 M Incidental finding on CT L 50 1b – – – LTF
3 47 M Hematuria, flank pain R 100 3b Neg Lung, Liver 2 DOD
4 69 F Hematuria R 80 3a – Bone-U, Local R 53 DOD
5 59 M Flank pain L 140 4 Pos – – LTF
6 67 M Fatigue, subcostal pain L 160 4 Pos Liver, LN 2 DOD
7 40 M – L 25 1a – None 127 NED
8 15 F Palpable ventral mass L 55 1b – Lung, Vertebral column 14 DOD
9 46 M Incidental finding L 100 2a Neg Local R 13 DOD
10 72 F Flank pain L 140 3a – – 4 DOD
11 21 F – R – 3a – – – LTF
12 14 M – L – 1a – None 12 NCRD
13 31 M Incidental finding on US L 55 1b – None 87 NED
14 57 M – L 100 3a Neg Lung, Liver, Vertebral column 81 DOD
15 40 F – R 110 3a – LN 65 NED
16 50 F – R 45 1b – None 31 NED
17 32 M Incidental finding B 15 1a – None 24 NED
18 60 F Incidental finding – 16 1a – – – LTF
19 66 F – R 60 1b Pos Adrenal gland – LTF
20 32 M – R 20 1a Pos Liver – LTF
21 17 F – R 35 1a – None 175 NED
22 36 F Shoulder pain R 120 3b – Scapula 13 AWD
23 40 F Incidental finding R 41 1b – None 24 NED
24 8 F Palpable ventral mass L 100 2b – – 321 NED
25 54 F – R 120 3a Neg None 10 NED
26 66 M Abdominal pain L 110 2b – None 4 NED
27 51 F – R 65 1b – Vertebral column 3 AWD
28 46 F Incidental finding L 110 3a Pos None 7 NED
†Symptoms: including any tumor-related symptoms; incidental finding indicates a symptomless tumor; −, no data. pT Stage: classification by AJCC
2016 TNM Staging System. §Node Status: nodal status at time of surgery; −, no lymph node was removed; Neg, negative; Pos, positive. A lymph node
metastasis that developed during the follow-up period is listed in the”Metastasis” column. *Metastasis: either found earlier or at the same time with the
primary renal tumor, or during the follow-up period; Bone-U, bone, exact location is unknown; −, no data; R, recurrence; LN, lymph node. ¶Status:
DOD, died of disease; LTF, patient is deceased, but lost to follow-up; NED, no evidence of disease; NCRD, not a cancer-related death; AWD, alive with
disease; −, no data
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Discussion
Clinicopathological Findings of Xp11.2 RCC
We reviewed 2804 nephrectomy cases and identified 28
Xp11.2 translocation RCCs. In our cohort its frequency was
lower, compared to literature data (0.99 vs. 1–4%) [22]. That
is due to the relatively large number of patients included in our
study, the analysis may roughly represent the ratio of Xp11.2
RCC in Hungary. In these neoplasms the characteristic cyto-
genetic change is the translocation involving the MIT family
transcription factor TFE3 gene [1]. These tumors were once
regarded as childhood malignancies, though because of the
significant overlapping features with clear cell and papillary
RCC and the limited cytogenetic data, some authors suggested
that the exact frequency in adults is underestimated [14]. In
our cohort 12 tumors occurred in patients who were less than
40 years old, only four tumors affected children, and the oldest
patient examined was 72 years old. Nine patients were symp-
tomatic and tumor-related pain was the most common symp-
tom. Only seven tumors did not produce any noticeable signs.
A link between previous use of chemotherapy and transloca-
tion RCC was reported [15], but in our study there was no
patient with a prior history of malignancy. Discriminating
Xp11.2 RCC from other subtypes of RCC is crucial for prog-
nostic and predictive reasons. It was suggested recently, that
patients with Xp11.2 RCCmay benefit frommTOR inhibitors
and VEGF-targeted agents [16, 17]. The diagnosis relies on
morphological features, immunohistochemical findings and
molecular pathological analysis. Xp11.2 RCC has no specific
macroscopic appearance; in fact most tumors resemble clear
cell RCC with a sulfur yellow cut surface along with foci of
hemorrhage and/or necrosis [9]. Xp11.2 RCC is usually diag-
nosed as a sizeable mass in the kidney. The mean size of our
tumors (78.5 mm) was larger than in the earlier reported series
[2, 14, 18]. In our previous analysis, only unclassified RCC
Table 3 Histological findings of
the investigated tumors PP
(%)
SP
(%)
CCs
(%)
ECs
(%)
Foamy
cells
IP ChC PB Necrosis ISUP
grade
1 5 95 50 50 – – – – + 4
2 40 60 30 70 + + – – – 2
3 1 99 20 80 – – – – + 4
4 50 50 90 10 – – – – + 2
5 – 100 10 90 – – – – + 4
6 – 100 5 95 – – – – + 4
7 – 100 100 – – – – – – 1
8 90 10 80 20 – – – – – 2
9 50 50 70 30 – – – – + 4
10 80 20 75 25 – – – – + 4
11 95 5 90 10 + – – – – 3
12 50 50 80 20 – – – + + 3
13 100 – 100 – + – + + + 2
14 10 90 60 40 – + – + – 2
15 80 20 70 30 – + – – + 3
16 90 10 75 25 + – – + – 3
17 100 – 100 – – – – + – 2
18 5 95 30 70 + – – + – 3
19 10 90 80 20 – – – + + 2
20 – 100 95 5 – – – + + 4
21 – 100 30 70 – – – + – 2
22 50 50 90 10 – – – – + 3
23 – 100 80 20 + – – – + 3
24 – 100 60 40 – – – – – 3
25 80 20 30 70 + – – + + 3
26 95 5 90 10 – + – – + 3
27 100 – 50 50 – – – + – 3
28 90 10 80 20 – – – – + 3
PP, indicates papillary pattern; SP, solid pattern; CCs, clear cells; ECs, eosinophilic cells; IP, intracytoplasmic
pigment; ChC, cholesterol clefts; PB, psammoma bodies; +, present; −, absent
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and collecting duct carcinoma were larger than Xp11.2 RCC
[19]. An invasion of the renal vein and/or the sinus is quite
frequent; at least one of these was noticed in 12 patients.
Metastatic spread to the regional lymph nodes or distant or-
gans was observed in 32% of the cases; six patients had ne-
phrectomy at the pM1 stage. Our observations on the rate of
pT3/pT4 stage and the occurrence of metastasis are in accor-
dance with the literature data [14]. This late stage discovery
might partly explain the generally poor outcome in Xp11.2
RCC.
Microscopic Features of Xp11.2 RCC
Microscopically the predominant growth patterns are papil-
lary, tubular, nested and mixed. A striking histological finding
is the presence of psammoma bodies [2, 18]. A different dis-
tribution was observed in our cohort, as a result of solid pat-
tern observed as most frequent, followed by papillary and
mixed architecture. Tumors were composed of mainly clear
cells in 19 and of eosinophilic cells in 7 cases. Additionally the
simultaneous presence of both cell types was noted in two
Fig. 1 Representative images of
typical morphological features of
Xp11.2 renal cell carcinomas. (A)
Solid-nested pattern with
admixture of eosinophilic and
clear cells. (B) Alveolar pattern
populated by eosinophilic cells.
Psammoma bodies are also
present. (C) Papillary pattern with
voluminous clear cells and
psammoma bodies. D
Occasionally the nuclei are near
the apical surface of the cells and
they mimic clear cell papillary
renal cell carcinoma. The arrows
indicate the psammoma bodies.
All images have a magnification
factor of 200x
Fig. 2 Representative images of
Xp11.2 renal cell carcinomaswith
unusual morphological features.
(A) Tubular pattern resembling
low-grade clear cell carcinoma.
(B) Solid pattern with foci of
comedo-like necrosis. (C)
Rhabdoid tumor-like pattern. (D)
Anaplastic carcinoma
appearance. All images have a
magnification factor of 200x
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cases. Psammoma bodies were observed in 11 cases. Foamy
cells and intracytoplasmic pigment are common features in
papillary RCC; hence their extensive presence can cause dif-
ferential diagnostic problems. However, in our cohort both
foamy cells and intracytoplasmic pigment occurred in a small
proportion of cases and they did not have a predominant
papillary pattern. Microscopic tumor cell necrosis was ob-
served in 60% of tumors. Although the effect of necrosis on
the outcome in Xp11.2 RCC is doubtful, in a large set of RCC
patients, poor prognostic effect of microscopic tumor necrosis
was identified earlier in the three most frequent types of RCC
[20]. Cases with atypical architecture can cause serious
Table 4 Immunohistochemical
results of the analyzed cases CA9 CK7 CD10 AMACR MelanA HMB45 Cathepsin K TFE3 IHC TFE3 FISH
1 N N D N N N N D +
2 N N D N N N N D +
3 N N N N N N N D +
4 N N D D N N D D +
5 N N D N N N N D +
6 N N N N N N N D +
7 N N D F N N N D +
8 N N D D N N N D +
9 N N N N N N N D +
10 N N D N D N N D +
11 N N D F N N F F NA
12 N N D D N N N D NA
13 N N D D N D N D +
14 N N D D N F D D +
15 N N N N D N N D +
16 N N D D N N N D +
17 N N D F N N N D +
18 N N F D N N N F +
19 N N F N N N N D +
20 F N N N N N N N +
21 N N D N N D D D +
22 N N F D N N F D +
23 N N N N N N N D +
24 N N N N D N N F NA
25 N N D D N N N F +
26 N N D D F N F F +
27 F N D N N N N N +
28 F N F F N N N D +
N, indicates negative; F, focally positive; D, diffusely positive; NA, data not available
Fig. 3 Representative images of
the immohistochemical features
of the analyzed tumors. (A)
Tumor cells display diffuse TFE3
nuclear positivity. (B) Cathepsin
K expression in an Xp11.2 renal
cell carcinoma. (C) Diffuse
cytoplasmic and membranous
CD10-positivity is frequently
seen in Xp11.2 renal cell
carcinomas. (D)MelanA
expression in Xp11.2 renal cell
carcinoma. All images have a
magnification factor of 200x
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diagnostic difficulties; namely, the morphological spectrum of
Xp11.2 RCC is quite broad, furthermore urothelial cell carci-
noma mimicking translocation RCC was reported as well
[13]. In our cohort, a case mimicking anaplastic carcinoma
and another with rhabdoid morphology were observed.
Some authors suggested that the specific translocation has an
influence on histological appearance [21]. Because of the ab-
sence of fusion partner analysis, we cannot argue for or against
this statement. The influence on the prognosis of the fusion
partner is yet unclear [23].
Immunophenotype of Xp11.2 RCC
Xp11.2 RCC is negative with CA9, CK7 and positive
with CD10 and AMACR [10]. In our series, both CA9
and CK7 were completely negative in almost every
case, except for CA9 in three samples. However, two
of these tumors were extensively necrotic, therefore we
concluded that the staining was related to hypoxia of
the tumor tissue. Diffuse CD10 labeling was noted in
60% of cases, while AMACR-positivity was observed
only in 50% of the tumors. MelanA and HMB45 ex-
pression is frequent in TFEB translocation RCC, never-
theless is rare in Xp11.2 translocation RCC [5]. Similar
proportion was described in our cohort; namely, MelanA
and HMB45 were posi t ive in 4 and 3 tumors
respectively. For the diagnosis of Xp11.2 RCC, TFE3
immunostaining is the most frequently used method.
The specificity and sensitivity of the immunohistochem-
istry were found to be 99.6% and 97.5% [24], although
in some cases false negativity and false positivity can
occur [23, 25]. Argani et al. described that the shorter
incubation time with automated detection system made
TFE3 IHC more sensitive, while the specificity of the
reaction decreased. For the false-negative results, some
authors declared that it can be caused by preanalytical
factors (e.g. fixation time) or by different analytical
methodologies applied (e.g. poor-quality antibodies and
inappropriate antigen retrieval) [13, 26]. There were on-
ly two tumors (patient #20 and #27) with TFE3-nega-
tivity and the remaining cases displayed a diffuse and
strong nuclear positivity. Therefore, in our analysis the
sensitivity of TFE3 immunohistochemistry correlates
with data of the earlier reports [24]. Cystine protease
Cathepsin K is a novel immunohistochemical marker
for Xp11.2 RCC, although the expression depends on
the fusion partner of the TFE3. This can serve as an
explanation of its expression in only approximately 60%
of Xp11.2 RCC [12, 27]. Six cases with Cathepsin K-
positivity were described, that is slightly under the re-
ported rate in literature [13]. The difference might be
related to the different translocation partners.
Fig. 4 Representative images of
the signal patterns seen in the
analyzed tumors. (A) Typical split
signals (red and green arrows) are
present in a male patient (patient
#17). (B) Truncated signal pattern
consisting of a pair of fused
signals (yellow arrows) and a
single red signal was observed in
patient #10. (C) Although signals
are separated (red and green
arrows), they are unusually close
to each other. In lymphocytes
normal fused signals (yellow
arrows) are present (patient #14).
(D) The loss of an entire break-
point region was observed in
patient #23. The yellow arrow
indicates the intact chromosome
X
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Genetic Markers of Xp11.2 RCC
Reverse transcription polymerase chain reaction (RT-PCR) is
a sensitive method for the identification of different kinds of
chimeric mRNA transcripts, though the limited availability of
frozen samples generally makes the testing problematic or
even impossible [28]. Cytogenetic karotyping is another clas-
sic methodology for recognizing structural changes among
chromosomes. Nevertheless it requires a special laboratory,
technicians and fresh material, hence the use of karotyping
in the routine diagnosis of solid tumors is limited. Currently
next-generation sequencing can be used to reveal the partner
genes and identify new ones, as Pei et al. did [29]. FISH
reactions have been performed on FFPE samples with satis-
factory for some time now. TFE3 break-apart FISH assay was
introduced in 2011 and since that it has become an indispens-
able diagnostic tool for Xp11.2 RCC [13, 30]. In our study the
diagnosis was supported with TFE3 break-apart FISH analy-
sis in 25 cases. The classic break-apart pattern was observed in
21 tumors and the truncated signal pattern was noted in 2
cases. For the latter cases, two explanations exist. First of
all, truncation effect of cutting the tumor cell nuclei is a
well-known problem in FISH assays on FFPE slides [13].
On the other hand, in our cases this was the dominant pattern.
In patient #9 a single red signal was seen in 100% of the
positive tumor cells, while in patient #10 split and a single
red signal was observed in 17% and 83% of the positive tumor
cells respectively. Therefore it is considered by our team that
the labeled part of the TFE3 was lost due to an atypical break
in the gene sequence. Atypical FISH patterns are known for
both epitheloid renal neoplasia along with soft tissue sarcomas
[30–32]. In patient #14 the signals were unusually close to
each other, and this phenomenon is the indicative of
intrachromosomal inversion [4]. In a female patient an entire
break-point region was completely missing from the majority
of the tumor cells. This was considered to be a result of an
atypical translocation. Otherwise, the histomorphology and
immunophenotype were concordant with Xp11.2 RCC, so
the final diagnosis was made on summary of the above-
mentioned results. Such signal pattern was presumed earlier
[30], though to our best knowledge, this is the first report of
such a signal pattern in Xp11.2 RCC. Optimized TFE3 break-
apart FISH assay is extremely useful in routine diagnosis and
pathology consultation [27]. However, FISH analysis has its
own limitations as well, whereas poor fixation, inappropriate
hybridization, and/or extensive contamination with normal
stromal cells can lead to negative results. It must be stated that
b r e ak - apa r t F ISH te s t ha s l ow sens i t i v i t y fo r
intrachromosomal or paracentric inversions like in RBM10-
TFE3 and NonO-TFE3 RCCs [33]. In these cases, despite
the typical microscopic appearance and the characteristic
immunophenotype, FISH can provide equivocal or even neg-
ative results. In this particular scenario, one must be really
cautious about setting the diagnosis as Xp11.2 RCC, and fu-
sion partner analysis (if available) by RT-PCR or RNA se-
quencing should be considered [33].
Clinical Course of Xp11.2 RCC
Some authors previously reported that Xp11.2 RCC had an
indolent course [35–38]. Camparo et al. calculated a mortality
rate of 13.6% for Xp11.2 RCC from their analysis and litera-
ture data, although the follow-up period was quite short [14].
A fascinating case of Xp11.2 RCC was reported by Mangel
et al. [38]. In their report, rapid progression of a stable disease
was noted after the patient became pregnant, and the authors
considered that the enormous tumor evolution was triggered
by cytokines and hormones produced by the placenta, espe-
cially human chorionic gonadotropin. In our cohort the medi-
an follow-up time was 14 months. In the meantime, 33% of
the patients died from a cancer-related cause. This indicates
the fact that Xp11.2 RCC has the same mortality rate as the
calculated rate for overall RCC patients [39].
The strength of our study is the relatively high number of
systematically analyzed cases by descriptive light-microsco-
py, a panel of immunohistochemistry and FISH analysis. Two
tumors with a fairly unusual morphology was included, one
with anaplastic carcinoma appearance and another with
rhabdoidmorphology. Unique FISH pattern with the complete
loss of the labeled break-point region was observed. The clin-
ical follow-up was not complete for all patients, however, the
mean follow-up period was more than 4 years.
One limitation of this current study is the absence of cyto-
genetic studies and the data for fusion partner analysis.
In summary, the results of 28 Xp11.2 RCC cases were
presented from a large surgically treated series of RCC.
Xp11.2 RCC is a rare form of renal cell carcinoma; and it is
accounted for 0.99% of all RCC cases in our study. In adults
the outcome is rather poor. Cases with an unusual
histomorphology may cause differential diagnostic problems,
though the use of antibodies in combination can improve the
diagnostic performance. Finally, to avoid false negative and
false positive cases, the use of TFE3 break-apart FISH studies
and/or fusion partner analysis are strongly recommended.
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